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ABSTRACT OF THE DISSERTATION 
Synthesis of Simplified YM-254890 Analogs 
By 
Derek Thomas Rensing 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2016 
Professor Kevin D. Moeller, Chair 
  
G Protein Coupled Receptors (GPCR’s) are responsible for a multitude of physiological, 
cellular, and disease processes.  GPCR’s signal through non-receptor based heterotrimeric G 
proteins and since G proteins effectively mediate GPCR signal transduction they are attractive 
therapeutic targets. However, little is known about the signaling pathways associated with 
individual G proteins. For this reason, there is intense interest in the development of chemical 
probes that can help identify the downstream biochemistry of individual G proteins.  
One small molecule natural product that shows promise along these lines is YM-254890 
(YM).  YM has been shown to specifically and potently inhibit the α subunit of the G protein 
Gq. Further studies of the natural product have been hampered because YM has yet to be 
synthesized due to its complex cyclic depsipeptide structure.  By studying the X-ray crystal 
structure of YM bound to Gqα, the contact points between the molecule and the protein have 
been elucidated, and from this we targeted a simplified analog substructure.  This analog 
structure preserves the protein contact points of YM while reducing the complexity of 22 
member ring structure of YM. The heart of the project undertaken centers on the development of 
 xiv
a convergent synthetic route to the analog’s core ring structure that is general enough to enable 
the synthesis of a variety of derivatives in the future.   
 To this effect we have synthesized two different YM analogs.  The first, WU-07047, was 
completed with an overall yield of 6.4% and a longest linear reaction sequence of 10 steps. Initial 
biological testing of WU-07047 has shown that the simplified molecule is biologically active, 
albeit at a less potent level than YM. We currently have multiple collaborators testing the 
effectiveness of WU-07047 in different in-vivo studies. Before undertaking further biological 
studies in our labs, we wanted to increase the potency of the molecule.  
 To this end we reintroduced an intramolecular hydrogen bond in the molecule that had 
been lost in simplified WU-0747 molecule.  The 2nd molecule synthesized, WU-09060, was 
completed using the same convergent synthetic approach developed for WU-07047 and yielded 
the target molecule with an overall yield of 1.8% and a longest linear reaction sequence of 10 
steps.  Initial biological testing has shown that the reintroduction of the intramolecular hydrogen 
bond has had little effect on the potency of the molecule and therefore is not worth the extra 
synthetic effort.  During the synthesis of the WU-09060 molecule we were also able to probe the 
effects of the top bridging structure of the molecule on ease of overall molecule synthesis, which 
has larger implications on the synthesis of this class of molecule. 
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Chapter One 
Introduction and Background 
1.1 G Protein Coupled Receptors and Their Associated G Proteins 
G protein coupled receptors (GPCRs) and their associated G proteins play critical roles in 
an extraordinary range of cellular, physiological, and disease processes.1,2,3 In these events, 
hundreds of GPCRs signal through heterotrimeric G proteins that are made by combining one of 
16 G α subunits, with one of 5 G β isoforms and one of 13 G γ subunits. The picture is 
complicated by the fact that each GPCR often couples to more than one G protein, that several 
GPCRs often work in concert with each other, and that a set of G proteins control a given 
process. The combination of these features leads to a great deal of diversity, and we do not 
understand the functional consequences of this complexity. Besides using pertussis toxin to 
inhibit activation of Gi/o class G proteins,4,5,6,7 the biochemical community relies on analyzing G 
protein function genetically as a means to unravel this complexity. However, this approach can 
be complicated by redundancy between closely related G protein subunits or by cellular 
adaptations such as rewiring signaling pathways when one piece has been removed by deletion 
or knockdown. By comparison, chemical biology approaches to investigate G protein signaling 
pathways offer an opportunity to determine the acute function of specific G proteins. For this 
reason, small molecule ligands that directly target selected G proteins to modulate their activity 
are potentially very valuable as probes of biological function and as avenues to develop 
therapeutics. 
G protein activation can be explained using the catalytic cycle presented in Figure 1.1.  
Part A shows the resting state of the catalytic cycle.  At this point, the transmembrane GPCR is 
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associated with the heterotrimeric G protein.  The heterotrimeric G protein is composed of three 
units: the α subunit and the βγ dimer.  When in its resting state guanosine diphosphate (GDP) is 
bound to the G protein α subunit.  When an extracellular ligand becomes associated with the 
GPCR (Part B) a conformational change in the receptor is induced.  When this occurs it weakens 
the association of the α subunit of the G protein with the bound GDP unit.  This causes the 
release of GDP and then the uptake of a guanosine triphosphate (GTP), as shown in part C.  
When GTP is bound by the α subunit, the α subunit dissociates from the βγ dimer.  The release  
Figure 1.1: GPCR Signal Transduction Pathway 
 
of the α subunit then allows it to interact  with downstream effectors (as presented in part D).  
Eventually a GTPase contained within the α subunit will hydrolyze the GTP to produce GDP (as 
presented in Part E).  Once this happens the α subunit will re-associate with the βγ dimer (as 
A
DE
CB
F
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presented in Part F) and the cycle can start over.  We have interest in studying the biology behind 
Part E, or how G proteins activate downstream effectors.  In order to do this we need a molecule 
that can halt this process. 
 
1.2 YM-254890 
The first such small molecule G protein inhibitor is YM-254890 (Figure 1.2), which is 
produced by an isolate of the chromobacterium sp. QS3666.8  YM-254890 (YM) potently (IC50 
= 0.15 nM) and specifically inhibits the α-subunit of the G protein Gq.9,10,11  Gq is a key signal 
transducer for many GPCR’s,3 and animal models have shown that YM reduces blood pressure,12 
inhibits thrombosis,13 and blunts neointima formation following vascular injury.12 All three 
effects are consistent with phenotypes of mice lacking Gq.3  
Figure 1.2: YM-254890 Structure 
 
Beyond YM’s biological activity the structure itself is extremely complex.  YM is a 
cyclic depsipeptide composed of seven amino acids, six being in the 22 member ring core.  It has 
11 different stereocenters as well as a dehydroalanine peptide unit.  All of this combined leads to 
a molecule that is potentially difficult to synthesize.  There have been many attempts to 
synthesize YM, and the molecule was the subject of an Innocentive contest.14  For this challenge, 
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Innocentive funded a 100,000 dollar cash prize for anyone who could produce a synthetic route 
to YM that yielded 1mg of the product.  No group who participated was able to find a route 
before the contest deadline was reached (There were 228 active solvers according to the contest 
website).14 
 In spite of its complexity and the difficulties associated with its synthesis YM is still 
appealing as an intriguing lead compound for building a family of molecules for selectively 
inhibiting G proteins. The α-subunits of the G proteins have a high level of homology, and the 
selectivity of YM has been ascribed to how its specific structure interacts with subtle features its 
Gαq binding site. It is easy to suggest that variants of YM might bind and inhibit other G  
proteins. However, testing this hypothesis is complicated by the two factors. YM is not readily 
available and hence cannot be modified easily, and again, YM is not easy to synthesize.  It is 
with this in mind that we turned our considerations to a functional synthesis of a YM analog. 
1.3 The Function-Oriented Synthesis Concept 
 When trying to perform a synthesis of complex natural product there are a few main 
hurdles that one must overcome.  One of these hurdles is that the more complex the molecule is 
generally means it will take more steps to synthesize.  This can become prohibitive on many 
levels when the molecule is something as complex as bryostatin for instance.  Bryostatin, 
pictured in Figure 1.3A, is a complex molecule obtained from marine bryozoa.15 There is intense 
clinical interest in bryostatin because of its ability to induce apoptosis in cells,16 its ability to 
modulate the immune system,17 and the fact that it has been shown to increase learning and 
memory function in animals, which has implications as a possible Alzheimer’s disease 
treatment.18  Researcher’s access to bryostatin is very limited however.  The yield for which 
 5
bryostatin is isolated from the marine bryozoa is only 0.00014%.19  This amount does not fulfill 
the demand for the molecule.   
Figure 1.3: A) Bryostatin & B) Simplified Bryostatin Analog21 
 
 Synthesizing bryostatin in a lab setting could be a viable alternative to natural isolation, 
but unfortunately the complexity of the molecule also complicates its synthesis, which takes over 
70 steps to complete.15  The issue at hand is not if a natural product can be made, but if it can be 
made in a fashion that will be applicable to supplying the demand researchers have.  A 70 step 
synthesis with 90 percent yields for every reaction (not realistic) would only yield 0.06% of the 
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material overall.  Also, the amount of time for each step and the work hours needed to perform 
such a synthesis would be cost prohibitive on a large scale.  In order for synthesis to be a 
plausible alternative from natural isolation the number of steps needs to decrease.  Paul Wender 
has popularized this issue, referred to as step economy.20  There are two possible ways to 
increase step economy.  One is to discover and create new chemical methodology, allowing you 
to perform multiple transformations in less steps with higher yields.  This is a very important 
way of completing natural product synthesis, but in the case of YM where most of the reactions 
are more common in nature (there are not many ways to revolutionize the formation of peptide 
bonds, esterifications, or protecting group changes) this is not as applicable.  The other more 
attractive option in our case is to use a Function Oriented Synthesis (FOS).   
 The main idea of FOS is that you can keep the pharmacaphoric parts (the parts of the 
molecule that are essential for the biological activity) of the natural product, but can simplify the 
rest of the molecule.  In other words, keep what you need and replace what you don’t with 
something simpler.  An example of a simplified Bryostatin analog is presented in Figure 1.3B 
which has similar biological activity as Bryostatin.21 This analog completed by Wender and co-
workers took less than 30 steps, more than 40 less steps than the shortest known synthesis of 
bryostatin.22   
 There are other issues related to natural product synthesis beyond step economy alone.  
For instance, molecules derived from natural sources (plants) are not designed for human 
therapeutic use and because of this can often have undesired side effects as well as non-ideal 
pharmacokinetic properties.  FOS can help avoid or circumvent these issues because you can 
design the molecule exactly as you want.  The same synthetic method used to synthesize the 
bryostatin analog presented in Figure 1.3B has been used to make over 40 different bryostatin 
 7
analogs, many of which have equal to better affinity for the protein kinase C (PKC) target than 
bryostatin itself, with some potencies 2-3 orders of magnitude greater.21   
 Bryostatin is not the only molecule simplified by FOC.  There are numerous examples of 
using FOC to make simpler molecules that still have the same or better affinity for their 
respective targets than the naturally isolated lead compounds.  Some examples of these are 
laulimalide,23 largazole,24 and immucillin-G25 among others.  We hope to use this same sort of 
approach in our research by designing a simpler version of YM.  If we can come up with an easy 
synthetic route to a YM analog, then we will not only be able test that analog, but also start 
making different analogs that possibly target different G proteins.    
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CHAPTER TWO 
SYNTHESIS OF SIMPLIFIED YM-254890 ANALOG 
2.1 A Functional Synthesis 
Figure 2.1: Crystal Structure Data from YM-254890 in Gqα Binding Site1 
 
 
It appears that YM inhibits Gq by binding a pocket in the α-subunit of Gq (Gαq) that 
locks the protein in an inactive conformation1 and prevents activation of the protein by GPCRs. 
The binding pocket for YM is found in all G protein subtypes, and yet YM specifically inhibits 
only Gαq.  The selectivity of YM for Gq is thought to depend on the unique features of the 
binding pocket for YM in Gαq (Figure 2.1). Our long-term goal in this project is to try and gain a 
better understanding of these features and the origins of YM’s selectivity for Gαq.  This 
knowledge will be used to first develop YM analogs that are not selective for Gαq and then 
engineer new analogs that are selective for the other Gα protein subunits. In this way, we hope to 
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develop a family of YM analogs that can be used to probe the role of specific G proteins in 
various physiological or disease processes.  
To date, two main complications have blocked efforts to develop a family of G protein 
inhibitors based on the YM structure. First, YM is not readily available which impedes efforts to 
use the natural product itself as a platform for building derivatives.  Second, YM has a complex 
cyclic depsipeptide core structure that has thwarted efforts to obtain a series of analogs by means 
of total synthesis.2  This complex structure led us to develop a functional synthesis, as described 
in section 1.3: The Function-Oriented Synthesis Concept, of the simplest molecule possible that 
still retains the activity of YM.  With a simplified YM analog in hand, we could then start 
focusing on the goals outlined in the previous paragraph.  With this in mind, we undertook the 
synthesis and initial biological testing of the simplified YM analog 2 (Figure 2.2b).  
We used the crystallographic data shown in Figure 2.1 to help determine a starting point 
for a simplified YM analog.  As shown in Figure 2.1, YM comes into contact with the binding 
pocket at many points on both the right and left side of the molecule through both hydrophobic 
interactions (shown as orange parenthesis) as well as through hydrogen bonding (shown as red 
dotted lines).1  The molecule also contains two intramolecular hydrogen bonds, which are 
thought to aid in the conformation stability of the molecule.  All of this is highlighted in Figure 
2.2a. The boxes highlight the regions of YM most responsible for binding to Gαq in an X-ray 
crystal structure of the YM-Gαq complex.1 The points in YM that make contact with Gαq are 
marked with the asterisks, and the numbers denote the intramolecular hydrogen bonds. 
What is important to note is that the top and bottom of the molecule only come into 
contact with the protein in two places.  So, between the two regions most responsible for YM-
Gαq binding are two bridging-groups which we proposed might not be essential.  We hoped that 
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these two bridging groups could be replaced with alkyl chains (Figure 2.2b) that would simplify 
the synthesis of YM analogs while allowing for the molecule to still bind and inhibit Gαq.   
Figure 2.2: A) YM-254890 with Highlighted Crystal Structure Binding Points B) Simplified 
YM-254890 Analog 
 
 
2.2 Retrosynthetic Analysis 
 The synthesis of the simplified YM-analog 2 was initially proposed to follow the overall 
plan suggested in Figure 2.3. The strategy called for the construction of three building blocks 
that would be assembled into an acyclic version of the molecule and then be cyclized with an 
olefin metathesis reaction. We settled on this convergent approach after considering both the 
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immediate and long-term goals of the project. To make extensive variations to the core structure 
of YM, we needed a way to make those variations without having to repeat the entire synthetic 
effort. So we required a route that built the molecule from pieces that could be readily varied, 
and the synthetic methodology necessary to vary those pieces. With this in mind, the approach 
outlined below had three main advantages. First, the synthetic approach can be easily altered in 
case any single reaction pathway to the product, or even a collection of pathways, failed.  
Second, the stereocenters and protecting groups in the left and right hand building blocks can be 
varied in the building blocks to provide easy access to multiple analogs.  Last, the amino acids 
and the bridges can be readily varied to provide attachment points for fixing the analogs 
synthesized to a surface. This final point was important because we eventually want to test the 
binding of these molecules to their G protein targets by using array based electrochemical 
impedance experiments. To this end, we envision attaching the molecules to the arrays with a 
linker that can be built off of one of the amino acids on the top or bottom bridge of the molecule. 
These locations in YM do not appear to bind the active site of Gαq.  
With that backdrop, we had a few specific goals in mind for the retrosynthesis of each of 
the three pieces.  The right-hand building block appeared to be a readily assembled coupling 
product from a 2-hydroxy-3-phenylpropionic acid derivative and a protected allylglycine.  
Beyond that we wanted to make sure that we would have easy access to any of the four 
diastereomers of this building block.  The left-hand building block is a dimer of β-hydroxy 
leucine with a C-terminal allyl ester. The allyl ester was integral to our overall plan since the 
double bond would be needed for the planned olefin metathesis to complete the synthesis and 
close the macrocyclic ring. With the left-hand building block we were primarily concerned with 
finding an orthogonal protecting group strategy that would allow for coupling of the two β-
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hydroxy leucine groups to form the dimer and attachment of the top-bridging piece. The top 
bridge is a simple extended amino acid derivative, which can be readily exchanged for a more 
complex bridge in future efforts.  
Figure 2.3: Retrosynthetic Analysis 
 
 
2.3 Right Hand Piece 
Figure 2.4: Right Hand Building Block 
 
The effort began with construction of the right-hand building block (Figure 2.4) in a 
manner that would allow us to access any possible stereoisomer of the material. The construction 
NH
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O
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O
2
1
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of this building block centered on an asymmetric Ireland-Claisen rearrangement to obtain one of 
the desired stereocenters, labeled as 1 in Figure 2.3 Claisen rearrangements are a very useful 
family of [3,3]-sigmatropic rearrangement reactions that allow for the generation of C-C bonds 
in a stereoselective fashion. The Ireland modification of the reaction proceeds through a well-
defined cyclic transition state that involves both an enolate-metal complex and a Lewis-acid that 
helps organize the three-dimensional geometry of the interacting species (Figure 2.6). Because of 
the well-defined nature of this transition state the chirality of ligands on the metal in the complex 
can be transferred to the substrate in a predictable fashion. The literature indicates that the best 
selectivity for the reactions is obtained when one accounts for the nature of the chiral ligand 
used, the Lewis-acid employed, the metal counterion for the enolate, and, for the amino acid 
based example we were interested in, the protecting group used on the amine.3  In our case, the 
very bulky Chinchona alkaloid quinidine (Figure 2.5) was used as the chiral ligand to impart the 
(S)-stereochemistry needed for the amino acid.3  For future syntheses, the (R)-amino acid can be 
attained using quinine as the ligand (Figure 2.5). The other three factors (protecting group, 
Lewis-acid, and base counterion) all help improve how tightly bound the transition state is by the 
Lewis acid and hence how much of a role the chiral metal ligands play in determining the 
structure of the transition state (Figure 2.6).  For example, the strongly electronegative TFA 
protecting group allows for a proposed lithium enolate dianion (Figure 2.6).3  It’s thought that 
both the enolate and deprotonated amide can bind both the lithium counterion and the metallic 
Lewis-acid (in our case aluminum isopropoxide) to form a very tightly bound bimetallic 
transition state where one side of the enolate is completely blocked by the sterically bulky ligand.  
This leads to very high enantioselectivty in the reaction, and in cases where it applies high 
diastereoselectivity.  
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Figure 2.5: Chinchona Alkaloids Used as Chiral Ligands3 
 
Figure 2.6: Proposed Bimetallic Ireland-Claisen Transition State 
 
For our specific synthesis, the allyl ester substrate for the Ireland-Claisen (2-1) was 
obtained in a 78% yield through an EDC coupling reaction between a trifluoroacetyl protected 
glycine and allyl alcohol (Scheme 2.1). Reaction conditions discovered by Uli Kazmeier3 were 
then used to perform the Ireland-Claisen reaction and afforded allyl glycine 2-2 in an 82% crude 
yield with and enantiomeric excess of 74%.  The reaction was not purified at this point because 
of difficulties associated with chromatographing the polar acid and the fact that using crude 2-2 
did not affect the subsequent protecting group reactions. The enantiomeric excess obtained from 
the Claisen-Ireland rearrangement was determined after the product was converted into 
compound 2-4, a process that generated a diastereomeric mixture.  
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Scheme 2.1: EDC Coupling and Ireland-Claisen Rearrangement  
 
The next step in the synthesis was to change the trifluoracetyl protecting group needed 
for the Ireland-Claisen rearrangement to the acetyl group needed in the final product (Scheme 
2.2).  Deprotection of the TFA group using K2CO3 in methanol and water followed by a 
protection reaction using acetic anhydride afforded the acetate protected allylglycine 2-3 (72% 
over 3 previous steps) that was subsequently coupled to methyl (S)-2-hydroxy-3-
phenylpropionate with the use of a Mitsunobu reaction to form product 2-4 in a 65% yield.  The 
reaction led to a mixture of diastereomers measured at a ratio of (87:13).  The mixture could be 
separated via column chromatography and only the pure major diastereomer was carried 
forward.  
 
 
 
 
 
N
H
O
OH
O
F
F
F
HO
N
H
O
O
O
F
F
F
HOBt, NMM, EDCl
CH2Cl2
24 h
78%
NH
O OH
O
F
F
F
82% crude yield
74% ee
Al(iOPr)3, Quinidine
LiHMDS
THF
-78οC - rt
48 h
2-1
2-2
 18
Scheme 2.2: Protecting Group Switch and Mitsunobu  Reaction 
 
Enantiomeric excess from the Claisen-Ireland rearrangement was calculated by 
measuring the integration difference of the terminal olefin protons of the two diastereomers in 
the crude NMR of compound 2-4, which were formed after the Mitsunobu coupling.  An 
example of the crude NMR and the integrations of the terminal olefin protons is show in Figure 
2.7a.  In this mixture, the major diastereomer was easy to identify. However, the minor isomer 
was more difficult. In order to make sure the peaks in the spectrum attributed to the minor 
diastereomer actually belonged to the minor diastereomer and not a side product, we 
independently synthesized the minor diastereomer to compare the spectra.  The chemistry had an 
added benefit in that it allowed us to confirm that the Mitsunobu reaction used in Scheme 2.2 did 
proceed with the stereoinversion typically associated with its SN2 type reaction mechanism (The 
key step presented in Figure 2.8a).  This inversion is imparted because in the Mitsunobu reaction 
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the alcohol in the substrate is converted into a leaving group and then displaced by the acid to 
forms the desired ester. While this inversion is typical of most Mitsunobu reactions, there are 
cases that show the opposite stereochemical outcome (Figure 2.8b).4  Hence, we needed to prove 
that we had the proper diastereomer before moving forward. 
Figure 2.7A: Crude 1H NMR Spectrum of Compound 2-4 
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Figure 2.7B: 1H NMR Spectrum of Compound 2-7 
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Figure 2.8A: Mitsunobu SN2 Type Reaction Mechanism 
 
 
Figure 2.8B: Mitsunobu Reaction with Retention of Alcohol Stereochemistry4 
 
In order to form the minor diastereomer for the analysis above it was easiest to change 
the alcohol stereocenter.  This synthesis was performed by using the allyl glycine derivative 2-2 
to form compound 2-5. In place of the Mitsunobu reaction used in the previous synthesis, an 
EDC coupling was performed to couple 2-3 to methyl (S)-2-hydroxy-3-phenylpropionate. This 
changed preserved the stereochemistry of the alcohol rather than invert it.  In order for the 
coupling reaction to work, both the TFA and acyl protecting groups used in the previous 
synthesis could not be used.  The reason for this problem will be discussed below in section 2.4 
below.  To avoid the problem, the TFA protecting group was exchanged for a BOC protecting 
group in a two-step procedure that led to N-Boc-allylglycine 2-5 in a 75% yield (Scheme 2.3).  
This was followed by a Steglich-type esterification which was performed using the carboiimide 
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derivative EDC and DMAP as a catalyst to afford compound 2-6 in a 60% yield. The BOC group 
was then removed with trifluoroacetic acid and replaced with an acetate group using acetic 
anhydride to give compound 2-7 in a 39% over two steps.  The spectral data for compound 2-7 
matched the minor diastereomer (an enantiomer of 2-7) obtained in the synthesis of compound 2-
4. This can be seen by comparing the crude NMR obtained from compound 2-7, Figure 2.7b, 
with the crude spectrum from compound 2-4.  While the shifts of the olefin peaks don’t match 
exactly, an observation that may be attributed to sample concentration, it is still clear that our 
hypothesis about the minor product in the original reaction was correct. With that said, the 
method used to make 2-7 illustrated above is not the one that we will use in the future. It is a low 
yielding and requires extra protecting group manipulations.  Instead, we will simply use the 
opposite alcohol enantiomer, methyl (R)-2-hydroxy-3-phenylpropionate, for the Mitsunobu 
reaction used in the original synthesis. In fact, with the availability of both chiral alcohols and 
both chiral ligands for use in the Claisen-rearrangement, all four stereoisomers of the right hand 
piece of the molecule should be readily accessible via the simpler Mitsunobu route.   
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Scheme 2.3: Synthesis of Other Diastereomer 
 
Knowing that we had the proper diastereomer in hand, the synthesis of the right hand 
piece of the molecule could be completed by cleavage of the methyl ester (Scheme 2.4), a 
reaction that proved more challenging than initially anticipated. Multiple attempts were made to 
selectively cleave the methyl ester.  Traditional methods such as hydrolysis with acid or base 
were not an option because they would not only scramble the stereocenters present, but would 
also hydrolyze the ester bond formed in the previous reaction.  It was decided to use an iodide 
source to cleave the methyl ester by an SN2-mechanism because it would avoid scrambling the 
stereocenters and be selective for the methyl ester because of sterics [the iodide attacks the 
methyl ester group CH3R1 (primary center) rather than the more substituted CHR3 center (tertiary 
center)].  To accomplish the reaction, multiple iodide sources were tested. It was found that using 
LiI in refluxing THF for 24 h allowed for isolation of an 82% yield of the desired acid.  Analysis 
of the product by proton NMR indicated that about 8% of the material racemized (showing the 
other diastereomer discussed previously) during the final deprotection step.  Other reaction 
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conditions utilizing other iodide sources or alternative solvents led to higher amounts of 
racemization.  Still, after recrystallization 50% of the pure building block could be obtained 
which was used in the final assembly of the molecule. Another 30% of the building block could 
be isolated that was contaminated with the minor diastereomer.  
Scheme 2.4: Methyl Ester Cleavage Reaction 
 
 
2.4 Left Hand Piece 
Figure 2.9: Proposed Retrosynthesis of Left hand Piece  
 
The synthesis of the left hand building block proved to be very challenging.  After 
employing the known methodology for the construction of syn-β-hydroxyleucine 2-9,5 our initial 
plan was to dimerize the amino acid derivative and then couple the dimer to the top bridge of the 
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molecule (Figure 2.9).  In order to dimerize the amino acids an orthogonal protecting group 
strategy was needed that would allow for the coupling of acid (A) with alcohol (B).  Four 
different protecting groups were needed.  For piece A, an acyl group was placed on the amine 
because it is in the natural product and therefore would not need to be removed again. The 
alcohol protecting group PG1 was envisioned as a TBS group.  For piece B we planned on 
protecting the acid as an allyl ester based on our overall synthetic plan (ring closing metathesis) 
and the nitrogen-protecting group PG2 was envisioned as an easily removable BOC group.   
The order of protection for the two β-hydroxyleucine monomers is presented in Scheme 
2.5.  The alcohol piece was constructed by first protecting the amine using Boc-anhydride and 
sodium bicarbonate to afford an 88% yield of compound 2-10, followed by esterification of the 
acid with methanol to give compound 2-11 in 84% yield.  We used the methyl ester in the 
preliminary studies because construction of the methyl ester was fast and gave high yields of the 
product.  At this point in the synthesis, we were more interested in studying the dimerization 
using multiple esterification conditions because we believed this would be a difficult part of the 
synthesis.  We could easily replace the methyl ester with an allyl ester later.  The acid piece was 
constructed by first acylating the amine using acetic anhydride with sodium hydroxide to give 
compound 2-12 in 93% yield, followed by TBS protection of alcohol in the molecule using TBS 
and triethylamine to give compound 2-14.  We believe that after the reaction we are actually 
getting a mixture of the target compound 2-14 as well as a double protected molecule 2-13 which 
has both the alcohol and acid TBS protected.  We came to this conclusion after studying the 
crude NMR spectra from this reaction which contains both the major product peaks from 2-14 as 
well as a smaller set of peaks which we have attributed to compound 2-13.  These can be seen in 
the crude spectrum from the reaction located in Appendix A.  In order to make sure all of 
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compound 2-14 was obtained we used mildly basic conditions on the crude mixture to obtain the 
desired product.  The reaction afforded inconsistent yields. In the best case, it gave rise to 
compound 2-14 in a 78% yield over the two steps. However, most times either the TBS ester and 
ether were both deprotected or we could not get all the product back from column purification 
which led to much lower yields.  The inconsistency of the reaction was very problematic, but 
nevertheless enough of the desired acid was obtained to be able to explore the subsequent 
coupling reaction.  
Scheme 2.5: β-hydroxyleucine Protecting Group Strategy 
 
 In order to couple the two β-hydroxyleucine monomers, an EDC based Steglich coupling 
reaction was used (Scheme 2.6).  To our surprise the reaction did not work at all yielding only a 
mix of the starting materials and minor side products.  This was initially surprising because as 
the reaction was monitored via TLC the disappearance of the acid starting material was 
observed.  As illustrated in Figure 2.10, the TLC obtained from the crude reaction product 
showed two spots. One was attributed to the starting alcohol and the other to what was initially 
described as an unknown side product.  The unknown side product was stable enough to survive 
column chromatography.  However, we were surprised to find that after allowing the aliquots 
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from the column containing the side product to sit over the weekend open to the air, the TLC 
changed.  The spot attributed to the side product disappeared and a new spot closer to the 
baseline appeared in the same area as the original acid starting material.  When an NMR was 
obtained of this material, the sample was very clearly the starting acid.  What we learned after 
carefully studying the spectrum of the crude material and conducting a detailed literature search 
was what we were actually seeing was the formation of a 5-oxazolone product.6   
Scheme 2.6: 5-Oxazolone Side Product 
 
Figure 2.10: TLC Analysis of 5 Oxazolone Side Product 
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proton on the acylated nitrogen is too acidic leading to a nucleophilic oxygen that traps the 
activated ester needed for the coupling reaction (Scheme 2.6).6  The 5 member ring is unreactive 
toward attack by the alcohol nucleophile so no reaction can occur.  In contrast, carbamate based 
protecting groups like Boc and Troc are less prone to 5-oxazolone ring formation, presumably 
because of their weaker acidity. While the use of such a group would require a later change to 
the acetyl group in the synthesis, it would avoid the side reaction.  This is the same phenomenon 
that led us to juggle the protecting groups during the synthesis of the right hand piece of the YM 
analog described above in section 2.3. In that synthesis, an acyl protected amine was compatible 
when the two pieces of the molecule were combined with a Mitsunobu reaction, but a BOC-
protecting group was needed when the pieces were coupled with a Steglich-type  esterification.       
 Because the aforementioned coupling reaction did not work, we decided to take a very 
hard look at our protecting group strategy. The key was to come up with a general strategy that 
could be used consistently for the construction of a variety of analogs. To this end, we decided to 
change the acyl protecting group to a 2,2,2-trichloroethyl chloroformate (Troc) protecting group 
on the acid monomer (Scheme 2.7).  This switch from an acyl to carbamate based protecting 
group would help bypass the 5-oxazolone ring formation problem, and the use of the reductively 
cleavable Troc-group would afford an orthogonal strategy for its subsequent removal later in the 
synthesis.  After significant experimentation, the strategy shown for the conversion of 2-9 into 2-
19 shown in Scheme 2.7 was developed.   From the acid protected β-hydroxyleucine monomer 2-
9, we installed the Troc- protecting group using Troc-chloride and sodium bicarbonate in a 
THF/Water solvent system to afford product 2-16 in a 71% yield.  We then wanted to change our 
alcohol TBS protection strategy used in Scheme 2.5 to something that would avoid the need to 
deprotect a silyl ester and would in so doing lead to more reliable yields of the product. To do 
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this, we decided to first protect the acid with an allyl group; a transformation that was 
accomplished in an 85% yield by treating compound 2-16 with allyl bromide and sodium 
bicarbonate in DMF. The alcohol in 2-17 was then protected using t-butyldimethylsilyl triflate 
and 2,6-lutidine to form product 2-18 in an 88% yield.  A Pd(0)-catalyzed cleavage of the allyl 
ester using Pd(PPh3)4 with morpholine in THF afforded the finished acid monomer 2-19 in an 
86% yield.  Even though this synthetic route is one step longer than the original strategy, the 
yields are higher and the chemistry more reproducible.  With the acid in hand, the alcohol 
coupling partner was modified so that it contained the allyl ester group needed for the eventual 
cyclization reaction instead of the simpler methyl ester used in the model studies. This was 
accomplished via allylation of compound 2-10 to give compound 2-15 in an 89% yield.  
Scheme 2.7: New Protecting Group Plan 
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 With our new protecting group strategy in place we tested multiple esterification reaction 
conditions for coupling the two building blocks.  These are presented in Table 2.1.  A number of 
different classic coupling reagents were tested including the phosphonium and uronium based 
coupling reagents PyBop and HATU with yields topping out in the middle teens (examples 1-3).  
We then tried converting the acid moiety to a number of other leaving groups. The use of  
fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate (TFFH) to form an acid 
fluoride (4) for the coupling reaction led to a 28% yield of the desired ester, a classic carboiimide 
based Steglich esterification using EDC and DMAP (5) led to only a 29% yield of the coupled 
product, and finally the generation of a mixed anhydride from the acid using 2,4,6-
trichlorobenzoyl chloride led to a subsequent coupling reaction that afforded only a 30% yield of 
the desired product (6). The yields of the three reactions were all within experimental error of 
each other so we decided to proceed with the simpler Steglich esterification conditions for 
further optimization. A number of different reaction conditions for the Steglich reaction were 
varied (Table 2.2).  It was found that an excess of DMAP and the alcohol, as well as running the 
reaction in as little solvent as possible, raised the yield of the coupled product obtained. Using 
the optimized conditions the fully protected syn-β-hydroxyleucine dimer 2-20 was obtained in a 
yield of 65%. 
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Table 2.1: Esterification Reactions 
 
 Coupling Conditions % Yield 
1 PyBOP/CH2Cl2 0 
2 HATU, DBU/DMF 17 
3 HATU, DBU, DMAP/DMF 15 
4 TFFH, DMAP/CH2Cl2 28 
5 EDCl, DMAP/CH2Cl2 29 
6 , NEt
3
, 
DMAP/THF, CH
2
Cl
2
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Table 2.2: Steglich Esterification Optimization 
Eq. of 
EDCl 
Eq. of 
DMAP 
Solvent Time 
(hrs) 
Other 
Changes 
% 
Yield 
1.2 1.3 CH2Cl2 24 None 29 
1.2 1.3 CH2Cl2 48 None 29 
1.2 1.6 CH2Cl2 24 None 54 
1.2 2.5 CH2Cl2 24 None 52 
1.2 1.5 DMF 3 
Microwave 
50
ο
C 
0 
1.2 1.8 CH2Cl2 24 
2.6 eq. of 
alcohol. 
Conc. rxn. 
65 
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2.5 Adding the Top Bridge and Finishing the Molecule 
The next step of the sequence was to remove the Boc-protecting group from the newly 
formed dimer 2-20 and replace it with the top bridge of the simplified YM analog.  
Unfortunately, the deprotection reaction proved to be problematic.  When compound 2-20 was 
subjected to Boc-deprotection conditions, trifluoroacetic acid in dichloromethane, and then 
subsequent coupling to the bridging piece, no product was obtained.  The reason for this reaction 
failure was not studied.  The Boc protected amine strategy was useful while studying 
esterification reactions, but overall was an unattractive synthetic plan. It would be better to not 
have to juggle the protecting group at this late stage of the synthesis at all. Hence, a strategy was 
devised that first coupled the top bridge of the molecule to the hydroxyleucine monomer, which 
cuts out the subsequent deprotection and coupling steps with the more advanced dimer 
intermediate. To this end, a mixed anhydride of the Boc-protected 8-aminooctanoic acid was 
prepared and then treated with 2-9 in the presence of sodium hydroxide, Scheme 2.8. This 
resulted in the formation of amide 2-21 in an 83% yield. Compound 2-21 was then converted 
into the C-terminal allyl ester 2-22 in a 77% yield using allyl bromide and sodium bicarbonate. 
Scheme 2.8: Adding the Top Bridge 
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The pieces of the molecule were then assembled into the final product as outlined in 
Scheme 2.9. The effort began by coupling the two β-hydroxyleucine building blocks 2-19 and 2-
22 using EDC and DMAP in dichloromethane to afford a 59% of the complete left hand building 
block 2-23.  Because the acetate group could not be added to the molecule prior to the coupling 
reaction, the Troc group in 2-23 was exchanged for the acetate following the coupling reaction. 
Since the right hand portion of the molecule is more difficult to scale, it was more efficient to 
conduct the exchange at this point in the synthesis rather than waiting to accomplish the 
transformation after assembly of the entire molecule. The TBS protecting group was then 
removed (again to avoid the additional step following construction of the entire molecule) to give 
compound 2-24 in 51% yield over 2 steps.  This was followed by deprotection of the N-terminal 
Boc group of the molecule using standard conditions and subsequent coupling of the resulting 
amine to the right hand building block 2-8 to afford cyclization substrate 2-25 in 55% yield over 
2 steps.  This coupling was performed with COMU, a highly active third generation uronium-
type amide coupling agent (Figure 2.11).7    
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Scheme 2.9: Finishing the Molecule 
 
Figure 2.11: COMU Coupling Agent Structure 
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The final step of the synthesis was a ring closing olefin metathesis reaction which was 
conducted with a second generation Grubbs’ catalyst.8 The reaction ran very well and afforded a 
77% yield of the 22-membered ring product 2 which we refer as WU-07047.8  Given the size of 
the ring generated we were extremely happy the cyclization was not problematic. As for the 
choice of the second generation Grubb’s catalyst, it was used because it was already available in 
the lab. Since the reaction worked so well, we have not explored other catalysts. The alkene 
formed from the olefin metathesis was determined to be primarily, if not completely, the trans 
isomer (the minor isomer was not observed by proton NMR).  The proton NMR data from 
product was taken in CDCl3, but it did not show clear splitting patterns of the alkene protons.  A 
small amount of the compound was dissolved in DMSO-d6. In previous studies, we found that 
the use of DMSO can alter the hydrogen bonding structure of the molecule in solution and 
thereby alter the conformation of the molecule and the NMR spectrum obtained for it. We hoped 
that using DMSO-d6 as the solvent for the NMR would alter the conformation of the molecule 
and enable us to elucidate the alkene coupling constant. The resulting spectrum is shown in 
Figure 2.12. Clearly, the splitting patterns and coupling constants for both alkene protons can be 
seen.  The 15.2 Hz coupling constant for the vinyl protons clearly indicated the trans alkene.   
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Figure 2.12: Olefin 1H NMR coupling 
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 The result of this project is a convergent synthesis with a longest linear sequence of 10 
steps and an overall yield of 6.4%.  
 
2.6 Biological Efficacy 
Initial biological testing of WU-07047 has shown that the simplified molecule is 
biologically active, albeit at a less potent level than YM.4,8 We tested our molecule in a receptor 
assisted [35S] GTPγS binding assay.8  The way this assay works is predicated upon the fact that 
once a GPCR is activated the α subunit of the G protein exchanges GDP for GTP, as presented 
in Figure 1.1.   Since we are using [35S] labeled GTP, we can monitor the uptake of GTP.  The 
less GTP that is taken up by the molecule the better the inhibitor, our molecule, is working.  We 
used a commercially available cyclic depsipeptide, UBO-QIC9, which is very similar in structure 
and activity to YM as a reference molecule and compared both it and WU-07047 to a DMSO 
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control.  Both molecules are presented in Figure 2.13.  A more in depth description of this assay 
and the details associated with it are located elsewhere.8  
Figure 2.13: UBO-QIC and YM-254890  
 
The results of our study are presented in Figure 2.14.  It appears that both the WU-07047 
and UBO-QIC compounds display similar efficacy in the inhibition of [35S] GTPγS uptake (up to 
40% inhibition).8  In our assay the potency of WU-07047 is less than that of the UBO-QIC 
compound, although only by roughly half an order of magnitude.  (WU-07047 binds in at a 50 
µΜ concentration where as the UBO-QIC compound accomplishes similar binding at a 10 µΜ 
concentration.)  The assay was not completed with a dose response curve because of a limited 
stock of receptor and a desire to use said stock on the analysis of a more potent analog.   
While the WU-0747 molecule seems to have lost some potency its ability to inhibit Gα 
signaling means it was a good starting molecule for our synthetic efforts.  Before undertaking 
further biological studies in our labs, dealing with selectivity etc., we wanted to see if we could 
identify a different analog that had an increased affinity for Gqα.  In order to accomplish this we 
had revisit our original design. 
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Figure 2.14: Receptor-Assisted [35S] GTPγS Binding Assay8  
 
 
2.7 Experimental Procedures for Chapter Two Compounds 
 
[Compound 2-1]  To a stirred solution of N-trifluoroacetyl glycine (2.5179 grams, 14.7 mmol) 
and hydroxybenzotriazole (3.1644 grams, 20.5 mmol) in CH2Cl2 (40mL) was added allyl alcohol 
(1.10 mL, 16.2 mmol).  N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride or 
EDCl (3.9512 grams, 20.6 mmol) was dissolved in CH2Cl2 (40 mL) and added to the reaction 
flask followed by 4-methylmorpholine (1.60 mL, 14.6 mmol).  The reaction was stirred at room 
temperature for 18 hours at which time the organic mixture was washed with a saturated 
NaHCO3 solution (3x50 mL).  The aqueous layers were back extracted with CH2Cl2 (2x50 mL).  
All organic layers were combined and dried over MgSO4 and then concentrated to give 2.7078 
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grams of crude product mixture which was purified via flash chromatography (silica gel, 3:7 
ethyl acetate: CH2Cl2) to give compound 2-1 (2.4370 grams, 78% yield) as a yellow oil.   
FTIR (neat) 3325, 3094, 2953, 2894, 1753, 1719, 1557, 1182 cm-1;  1H NMR (300 MHz,  CDCl3 
) δ 6.89 (br, 1H), 5.92 (ddt, J=16.9, 10.7, 5.9, Hz, 1H), 5.37 (dd, J=17.3, 0.9, 1H), 5.31 (dd, 
J=10.6, 0.9, 1H), 4.71 (d, J=5.9 Hz, 2H), 4.17 (d, J=5.0 Hz, 2H);  13C NMR (75 MHz,  CDCl3 ) δ 
167.9, 130.9, 119.6, 66.7, 41.3;  HRMS m/z calculated for C7H8O3N1F3 [M+Na]
+ 234.0354, 
234.0348 observed.    
 
 
[Compound 2-2]  Compound 2-1 (0.4043 grams, 1.91 mmol) was subjected to a benzene (50 
mL) azeotropic distillation to remove any traces of water.  To the flask containing the dried 
compound 2-1 was added aluminum isopropoxide (0.4688 grams, 2.30 mmol) and quinidine 
(1.5526 grams, 4.79 mmol).  The reaction flask was cooled to -78C and THF (20 mL) was 
added followed by drop-wise addition of lithium bis(trimethylsilyl)amide or LiHMDS (10.5 mL 
of 1 M solution, 10.5 mmol) over 30 minutes.  The reaction was allowed to warm to room 
temperature and was stirred for 18 hours at which time it was diluted with diethyl ether (200 
mL).  The organic mixture was washed (carefully) with a 1M KHSO4 solution (100 mL, 50 mL) 
and then extracted with a saturated NaHCO3 solution (3x100 mL).  The aqueous extractions were 
acidified to pH=2 with solid KHSO4 (carefully) and extracted with diethyl ether (3x100 mL).  
The organic extractions were dried over MgSO4 and concentrated to give compound 5 (0.3306 
grams, 82% crude yield, 74% enantiomeric excess[The ee was determined by NMR after making 
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diastereomers of compound 2-2 to make compound 2-4. Example NMR given with compound 2-
4.]) as an orange oil.  Crude compound 2-2 was used in following reactions without further 
purification.  
FTIR (neat) 3298, 3090, 2988, 1713, 1645, 1557, 1212, 1179 cm-1;  1H NMR (300 MHz,  CDCl3 
) δ  6.77 (d, J=6.5 Hz, 1H), 5.70 (ddt, J=17.3, 10.7, 7.7, Hz, 1H), 5.24 (d, J=10.4 Hz, 1H), 5.22 
(dd, J=17.1, 1.5 Hz, 1H), 4.75 (dt, J=7.6, 1.5 Hz, 1H), 2.57 - 2.86 (m, 2H);  13C NMR (75 MHz, 
CD3OD) δ 173.4, 134.5, 119.0, 53.9, 36.4;  HRMS m/z calculated for C7H8O3N1F3 [M+Na]
+ 
234.0348, 234.0348 observed.    
 
 
[Compound 2-3]  Potassium carbonate (1.1253 grams, 8.14 mmol) was added to a mixture of 
compound 2-2 (0.3306 grams [all crude from last reaction shown above], 1.57 mmol) in a 15:1 
solution of MeOH:H2O.  This reaction solution was refluxed for 2 hours after which it was 
filtered to remove the potassium carbonate.  The filtrate was concentrated and used in the next 
reaction. 
Acetic anhydride (0.31 mL, 3.3 mmol) was added to a cooled (0 oC) solution of the 
concentrate from the previous reaction in water (18 mL).  The reaction solution was pH adjusted 
to pH=10 with a saturated sodium hydroxide solution and stirred for 4 hours at 0 oC before being 
allowed to warm to room temperature and stir for an additional 18 hours.  The reaction mixture 
was acidified to pH=2 with concentrated HCl and then diluted with MeOH (50 mL).  This 
mixture was then concentrated under reduced pressure to yield an orange salt.  This salt was 
washed with a 10:1 chloroform:MeOH solution and this organic wash was concentrated to yield 
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0.3372 grams of crude product mixture which was purified via flash chromatography (silica gel, 
gradient system starting with 7:3 ethyl acetate:hexane followed by 100% MeOH) to give 
compound 2-3 (0.2179 grams, 89% yield over 2 reactions and 72% yield over previous 3 
reactions) as an orange oil. 
FTIR (neat) 3317, 3083, 3984, 2934, 2540, 1725, 1644, 1550, 1439, 1377, 1203, 1144 cm-1;  1H 
NMR (300 MHz,  CDCl3 ) δ 10.71 (br, 1H), 6.69 (d, J=7.9 Hz, 1H), 5.72 (ddt, J=17.2, 10.3, 7.3 
Hz, 1H), 5.15 (d, J=16.4 Hz, 1H), 5.14 (d, J=10.8 Hz, 1H),  4.56 - 4.74 (m, 1H), 2.42 - 2.78 (m, 
2H), 2.06 (s, 3H);  13C NMR (75 MHz, CD3OD) δ 174.9, 173.3, 134.4, 118.8, 53.5, 36.9, 22.5;  
HRMS m/z calculated for C7H11O3N1 [M+Na]
+ 180.0631, 180.0627 observed.    
 
 
[Compound 2-4]  Compound 2-3 (1.0613 grams, 6.75 mmol) was subjected to a benzene (50 
mL) azeotropic distillation to remove any traces of water.  Triphenylphosphine (1.7825 grams, 
6.79 mmol) and THF (25 mL) were added to the flask and the solution was cooled to -30 oC.  
(S)-2-Hydroxy-3-phenylpropionic acid methyl ester (1.0256 grams, 5.69 mmol) was dissolved in 
additional THF (25 mL) and added to the reaction flask followed by drop-wise addition of a 40 
weight % solution of diethyl azodicarboxylate.  The reaction was stirred at -30 oC for 30 minutes 
and allowed to warm to room temperature and stir an additional 18 hours.  The reaction contents 
were diluted with THF (50 mL) and washed with a saturated NaHCO3 solution.  The organic 
layer was dried over MgSO4 and concentrated to give crude product which was purified via flash 
chromatography (silica gel, 100% ether) to give compound 2-4 (0.7650 grams of pure 
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diastereomer for 42% yield, as shown, and 0.4171 grams of mixed diastereomers [At the carbon 
bearing the NHAc from Ireland-Claisen rearrangement with 74% ee] for a total yield of 1.1821 
grams of product and a 65% overall yield) as a yellow oil.  
FTIR (neat) 3282, 3064, 3031, 3006, 2954, 1748, 1657, 1542, 1438, 1374, 1285, 1219, 1192, 
1147 cm-1;  1H NMR (300 MHz,  CDCl3 ) δ 7.13 - 7.41 (m, 5H), 5.89 (d, J=7.03 Hz, 1H), 5.38 
(ddt, J=17.1, 10.2, 7.0 Hz, 1H), 5.24 (X of ABX dd, J=9.5, 4.0 Hz, 1H), 4.95 (dd, J=10.1, 1.0 
Hz, 1H), 4.68 - 4.87 (m, 2H), 3.76 (s, 3H), 3.18 - 3.33 (A of ABX dd, J=14.4, 4.1 Hz, 1H), 2.99 - 
3.17 (B of ABX dd, J=14.4, 9.4 Hz, 1H), 2.41 - 2.58 (m, 1H), 2.24 - 2.40 (m, 1H), 1.98 (s, 3H);  
13C NMR (75 MHz,  CDCl3 ) δ 171.0, 169.42, 169.40, 135.53, 131.7, 129.2, 128.6, 127.2, 119.2, 
73.7, 52.5, 51.4, 37.2, 36.2, 23.0;  HRMS m/z calculated for C17H21O5N1 [M+Na]
+ 342.1312, 
342.1316  observed. 
 
 
[Compound 2-5]  Potassium carbonate (0.2178 grams, 1.58 mmol) was added to a mixture of 
compound 2-2 (0.0627 grams, 0.30 mmol) in a 15:1 solution of MeOH:H2O.  This reaction 
solution was refluxed for 2 hours after which it was filtered to remove the potassium carbonate.  
The filtrate was concentrated and used in the next reaction.  
Sodium Bicarbonate (0.0471 grams, 0.56 mmol) and the crude from the previous reaction were 
dissolved in a solution composed of water (2 mL) and THF (1 mL).  To this stirred solution was 
added BOC anhydride (0.10 mL, 0.44 mmol).  The reaction was stirred at room temperature for 
18 hours at which time the reaction was diluted with water (20 mL) and washed with Ethyl 
Acetate (2x25 mL).  The organic layers were then extracted with a concentrated sodium 
bicarbonate solution (2x25 mL).  All aqueous layers were combined and then adjusted to pH=2 
NHBoc
O OH
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with a 1N HCl solution.  The aqueous layers were then extracted with ethyl acetate (3x50 mL) 
and the organic extractions were dried over MgSO4 and concentrated to give compound 2-5 
(0.0479 grams, 75% yield over 2 steps).  The crude was used in the next reaction without further 
purification.  Because this reaction pathway was deemed unsuitable for future use compound 2-5 
was not fully characterized but the proton NMR spectrum obtained is located in Appendix A.  
 
 
[Compound 2-6] EDCI (0.1690 grams, 0.88 mmol) and 4-dimethylaminopyridine (0.1798 
grams, 1.47 mmol) were dissolved in CH2Cl2 (5 mL).  The solution was then added to a mixture 
of compound 2-5 (0.1585 grams, 0.74 mmol) and (S)-2-hydroxy-3-phenylpropionate (0.1328 
grams, 0.74 mmol) in a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to 
warm to room temperature and stir for 24 hours at which time it was diluted with CH2Cl2 (50 
mL) and washed with a saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers 
were back extracted with CH2Cl2 (2x30 mL).  All organic layers were combined, dried over 
MgSO4, and concentrated to give 0.3386 grams of crude product mixture which was purified via 
flash chromatography (silica gel, ether) to give compound 2-6 (0.1666 grams, 60% yield) as 
yellow oil.  Because this reaction pathway was deemed unsuitable for future use compound 2-6 
was not fully characterized but the proton NMR spectrum obtained is located in Appendix A.     
 
NHBoc
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[Compound 2-7] Trifluoroacetic acid (1 mL) was added to a stirred solution of compound 2-6 
(0.0914 grams, 0.24 mmol) in CH2Cl2 (2 mL).  Reaction was stirred at room temperature for 3 
hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in diethyl ether and concentrated three times to ensure all trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
A stirred solution of the crude product dissolved in dichloromethane (10 mL) was cooled to 0°C 
at which time acetic anhydride (0.05 mL, 0.05 mmol) was added followed by DMAP (0.0610 
grams, 0.50 mmol).  The reaction was stirred and allowed to warm to room temperature 
overnight.  After 18 hours the reaction contents were diluted with ethyl acetate (50 mL) and 
subsequently washed 1N HCl (2x50 mL), concentrated sodium bicarbonate solution (2x50 mL) 
and a brine solution (1x50 mL).  The organic layer was dried over MgSO4 and concentrated to 
give 0.0847 grams of crude product that was purified via flash chromatography (silica gel, 8:2 
diethyl ether: ethyl acetate) to give compound 2-7 (0.0300 grams, for 39% yield over 2 steps) as 
a yellow oil.  Because this reaction pathway was deemed unsuitable for future use compound 2-7 
was not fully characterized but the proton NMR spectrum obtained is located in Appendix A.    
  
NHAc
O O
O
O
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[Compound 2-8]  A solution of Lithium Iodide (0.0740 grams, 0.55 mmol) in THF (1 mL) was 
heated to reflux.  To this solution was added a solution of compound 2-4 (0.0438 grams, 0.14 
mmol) in THF (1 mL).  The reaction mixture was refluxed for 18 hours after which it was 
concentrated and then dissolved in water (5 mL) and pH adjusted to pH=2 with 1M hydrochloric 
acid.  The aqueous mixture was extracted with chloroform (3x10 mL).  The organic layers were 
combined, dried over MgSO4, and concentrated to give 0.0341 grams of compound 2-8, 82% 
yield (The substrate underwent minimal racemization as could be observed in the crude proton 
NMR.  To get diastereometrically pure compound 2-8 the product mixture can be recrystallized 
using ethyl acetate for a 50% yield of pure crystals and ~30% yield of mixed diastereomers.  For 
further reactions the pure form of compound 2-8 was used).    
FTIR (neat) 3337, 3054, 2986, 1740, 1704, 1601, 1562, 1421, 1265 cm-1; 1H NMR (300 MHz, 
DMSO-d6) δ 8.21 (d, J=8.2 Hz, 1H), 7.15 - 7.41 (m, 5H), 5.59 (ddt, J=16.9, 10.0, 7.3 Hz, 1H), 
5.04 (X of ABX dd, J=9.4, 4.1 Hz, 1H), 4.93 (dd, J=10.2, 1.9 Hz, 1H), 4.88 (dd, J=17.2, 1.9 Hz, 
1H), 4.36 (td, J=8.2, 5.3 Hz, 1H), 3.09 - 3.23 (A of ABX dd, J=14.1, 4.1 Hz, 1H), 2.94 - 3.08 (B 
of ABX dd, J=14.1, 9.4 Hz, 1H), 2.09 - 2.36 (m, 2H), 1.82 (s, 3H);  13C NMR (75 MHz, DMSO-
d6) δ 170.3(2 overlapping), 169.2, 136.4, 133.4, 129.4, 128.3, 126.8, 118.0, 73.1, 51.5, 36.6, 
35.3, 22.3; HRMS m/z calculated for C16H19O5N1 [M+Na]
+ 328.1155, 328.1157 observed.    
 
 45
 
[Compound 2-9]  The syn-β-hydroxyleucine starting material was synthesized and characterized 
according to previously reported literature procedures.5 
 
 
[Compound 2-10] Sodium Bicarbonate (1.5155 grams, 18.04 mmol) and compound 2-8 (1.1010 
grams, 6.00 mmol) were dissolved in a solution composed of water (20 mL) and THF (8 mL).  
To this stirred solution was added BOC anhydride (2.10 mL, 9.12 mmol).  The reaction was 
stirred at room temperature for 18 hours at which time the reaction was diluted with water (50 
mL) and washed with Ethyl Acetate (2x50 mL).  The organic layers were then extracted with a 
concentrated sodium bicarbonate solution (2x50 mL).  All aqueous layers were combined and 
then adjusted to pH=2 with a 1N HCl solution.  The aqueous layers were then extracted with 
ethyl acetate (3x50 mL) and the organic extractions were dried over MgSO4 and concentrated to 
give compound 2-10 (1.3134 grams, 89% yield).  The crude was used in the next reaction 
without further purification.  
FTIR (neat) 3406, 2977, 2934, 2876, 1696, 1515, 1394, 1368, 1250, 1166, 1056 cm-1; 1H NMR 
(300 MHz, DMSO-d6) δ 7.55 (br. s., 1 H), 5.70 (d, J=9.4 Hz, 1 H), 4.49 (d, J=8.8 Hz, 1 H), 3.78 
(d, J=9.4 Hz, 1 H), 1.77 (m, 1 H), 1.44 (s, 9 H), 1.03 (d, J=6.4 Hz, 3 H), 0.93 (d, J=6.4 Hz, 3 H); 
13C NMR (75 MHz, DMSO-d6) δ 176.1, 156.5, 80.2, 77.4, 55.9, 30.7, 28.3, 19.2, 18.8; HRMS 
m/z calculated for C11H21O5N1 [M+H]
+ 248.1492, 248.1494 observed.    
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[Compound 2-11]  4-methylmorpholine (0.22 mL, 2.0 mmol) was added to a stirred solution 
containing compound 2-10 (0.4492 grams, 1.82 mmol), hydroxybenzotriazole (0.3014 grams, 
1.97 mmol), and EDC (0.3792 grams, 1.98 mmol) in MeOH (12 mL). The reaction was stirred at 
room temperature for 18 hours at which time the organic mixture was diluted with CH2Cl2 (50 
mL) and washed with a saturated NaHCO3 solution (3x50 mL).  The aqueous layers were back 
extracted with CH2Cl2 (2x50 mL).  All organic layers were combined and dried over MgSO4 and 
then concentrated to give 0.4848 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 1:1 ethyl acetate:hexanes) to give compound 2-11 (0.3911 grams, 
84% yield) as a yellow oil.  Because this reaction pathway was deemed unsuitable for future use 
compound 2-11 was not fully characterized but the proton NMR spectrum obtained is located in 
Appendix A.   
 
 
[Compound 2-12] Acetic anhydride (0.62 mL, 6.6 mmol) was added to a cooled (0 C) 
solution of compound 2-9 (0.2414 grams, 1.64 mmol) in water (20 mL).  The reaction solution 
was pH adjusted to pH=10 with a saturated sodium hydroxide solution and allowed to warm to 
room temperature and stir for an additional 18 hours.  The reaction mixture was acidified to 
pH=2 with 1M HCl and then extracted with Ethyl Acetate (3x50 mL).  This mixture was then 
concentrated under reduced pressure to yield an orange salt.  This salt was washed with a 10:1 
OMe
O
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chloroform:MeOH solution and this organic wash was concentrated to yield 0.2874 grams of 
crude compound 2-12 for a crude yield of 93%.   The crude mixture was used in subsequent 
reactions without further purification.  Because this reaction pathway was deemed unsuitable for 
future use compound 2-12 was not fully characterized but the proton NMR spectrum obtained is 
located in Appendix A.     
 
 
[Compound 2-13 and 2-14] TBSOTf (0.70 mL, 3.1 mmol) was added to a stirred solution of the 
compound 2-12 (0.1921 grams, 1.02 mmol) in acetonitrile (1 mL).  This was followed by the 
addition of triethylamine (0.57 mL, 4.1 mmol).  The reaction was stirred for 24 hours at which 
time the reaction contents were diluted with concentrated sodium bicarbonate solution (50 mL) 
and subsequently extracted with CH2Cl2 (3x50 mL).  The organic layers were washed with water 
(50 mL) and brine solution (50 mL).  The organic layer was dried over MgSO4 and concentrated 
to give 0.2176 grams of crude product mixture that contained both compound 2-13 and 2-14.  
This crude spectrum is presented in Appendix A.  This spectrum contains what appears to be a 
product ratio of 1:2 of compound 2-13:2-14 respectively.   
 
 
[Compound 2-14] Potassium carbonate (0.4043 grams, 2.93 mmol) was added to a solution 
containing the crude mixture of products 2-13 and 2-14 (0.2176 grams) dissolved in 4 mL of 
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solvent mixture (2:1:1 THF:MeOH:H2O).  The reaction was stirred at room temperature for 1 
hour at which time the reaction was quenched with a concentrated citric acid solution (30 mL).  
The aqueous solution was extracted with ethyl acetate (3x30 mL).  The combined organic layers 
were washed with water (3x20 mL), brine (1x20 mL), then dried over MgSO4 and concentrated 
to give 0.1499 grams of crude product mixture.  The crude product mixture was purified via flash 
chromatography (silica gel, 9:1 ethyl acetate:MeOH) to give exclusively compound 2-14 (0.1027 
grams, for 33% yield over 2 steps) as a yellow oil.  Because this reaction pathway was deemed 
unsuitable for future use compound 2-14 was not fully characterized but the proton NMR 
spectrum obtained is located in Appendix A.  
  
 
[Compound 2-15] Allyl bromide (2.80 mL, 32.4 mmol) was added to a stirred solution of 
compound 2-10 (1.2685 grams, 5.13 mmol) and NaHCO3 (1.8868 grams, 22.46 mmol) in 21 mL 
of DMF.  The reaction was stirred for 48 hours at which time it was diluted with H2O (50 mL).  
The aqueous layer was extracted with ethyl acetate (3x50 mL).  The combined organic layers 
were then washed with H2O (2x50 mL), dried over MgSO4, and concentrated to give 1.4385 
grams of crude product mixture which was purified via flash chromatography (silica gel, 7:3 
hexane: ethyl acetate) to give compound 2-15 (1.2744 grams, 87% yield) as colorless oil.  
Because this reaction pathway was deemed unsuitable for future use compound 2-15 was not 
fully characterized but the proton NMR spectrum obtained is located in Appendix A. 
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[Compound 2-16]  A stirred solution of the hydrochloride salt of compound 2-9 (0.2228 grams, 
1.52 mmol) and NaHCO3 (0.2594 grams, 3.09 mmol) in 16 mL of H2O was cooled to 0°C.   In a 
separate flask 2,2,2-trichloroethoxycarbonyl chloride (1.04 mL, 7.56 mmol) was dissolved in 6 
mL of THF and cooled to 0°C.  The 2,2,2-trichloroethoxycarbonyl chloride mixture was then 
added drop-wise over 15 minutes to the reaction flask containing compound 2-9.  The reaction 
was allowed to warm to room temperature and stir for 48 hours at which time the reaction was 
diluted with H2O (20 mL).  The layers were separated and the aqueous layer was washed with 
ethyl acetate (2x25 mL).  The combined organic layers were then extracted with saturated 
NaHCO3 solution (3x20 mL).  All aqueous layers were combined and acidified to pH=2 with 1 
M hydrochloric acid and extracted with ethyl acetate (3x25 mL).  The combined extractions were 
then washed with brine (20 mL), dried over MgSO4, and concentrated to give compound 2-16 
(0.3439 grams, 71% yield) as a yellow foaming oil which was used without further purification.  
FTIR (neat) 3417, 3326, 3071, 2964, 2876, 2626, 1725 cm-1;  1H NMR (300 MHz,  CDCl3 ) δ 
6.71 (br, 1H), 6.12 (d, J = 9.6 Hz, 1H), 4.83 (A of AB, d, J = 12.0 Hz, 1H), 4.70 (B of AB, d, J = 
12.0 Hz, 1H), 4.62 (dd, J = 9.6, 1.9 Hz, 1H), 3.86 (dd, J = 9.4, 1.9 Hz, 1H), 1.89 – 1.73 (m, 1H), 
1.05 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H);  13C NMR (75 MHz,  CDCl3 ) δ 175.6, 155.3, 
95.3, 77.6, 74.7, 56.4, 30.7, 19.2, 18.7;  HRMS m/z calculated for C9H14O5N1Cl3 [M+Na]
+ 
343.9830, 343.9831 observed.  
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[Compound 2-17]  Allyl bromide (0.42 mL, 4.9 mmol) was added to a stirred solution of 
compound 2-16 (0.2552 grams, 0.80 mmol) and NaHCO3 (0.2880 grams, 3.43 mmol) in 3 mL of 
DMF.  The reaction was stirred for 48 hours at which time it was diluted with H2O (10 mL).  The 
aqueous layer was extracted with ethyl acetate (3x15 mL).  The combined organic layers were 
then washed with H2O (2x10 mL), dried over MgSO4, and concentrated to give 0.2972 grams of 
crude product mixture which was purified via flash chromatography (silica gel, 7:3 hexane: ethyl 
acetate) to give compound 2-17 (0.2435 grams, 85% yield) as colorless crystals.   
FTIR (neat) 3432, 2963, 2875, 1736cm-1;  1H NMR (300 MHz,  CDCl3 ) δ 5.92 (ddt, J = 17.2, 
10.4, 5.7 Hz, 1H), 5.82 (d, J = 9.6 Hz, 1H), 5.35 (dd, J = 17.2, 1.5 Hz, 1H), 5.27 (dd, J = 10.4, 
1.3 Hz, 1H), 4.81 (A of AB, d, J = 11.9 Hz, 1H), 4.74 (B of AB, d, J=11.9 Hz, 1H), 4.68 (d, J = 
5.7 Hz, 2H), 4.59 (dd, J = 9.6, 1.9 Hz, 1H), 3.79 (dd, J = 9.2, 1.9 Hz, 1H), 2.14 (s, 1H), 1.79 (m, 
1H), 1.05 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.7 Hz, 3H);  13C NMR (75 MHz,  CDCl3 ) δ 171.1, 
154.9, 131.4, 119.0, 95.4, 77.4, 74.7, 66.3, 56.2, 30.8, 18.9, 18.8;  HRMS m/z calculated for 
C12H18O5N1Cl3 [M+H]
+ 362.0323, 362.0325 observed.   
 
 
[Compound 2-18]  A stirred solution of compound 2-17 (0.2490 grams, 0.69 mmol) in 4 mL of 
CH2Cl2 was cooled to 0°C.  2,6-Lutidine (0.40 mL, 3.5 mmol) was added to reaction flask 
followed by triflouromethanesulfonic acid tert-butyldimethylsilyl ester (0.39 mL, 1.7 mmol).  
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The reaction was allowed to warm to room temperature and stir for 48 hours at which time the 
reaction was quenched with 15 mL of cold 1 M hydrochloric acid.  The aqueous layer was 
extracted with CH2Cl2 (3x15 mL).  The combined organic layers were washed with 1 M KHSO4 
(15 mL) and brine (15 mL).  The organic layer was dried over MgSO4 and concentrated to give 
0.4129 grams of crude product mixture which was purified via flash chromatography (silica gel, 
9:1 hexane: ethyl acetate) to give compound 2-18 (0.3163 grams, 96% yield) as a clear oil.   
FTIR (neat) 2956, 2931, 2884, 2858, 1746 cm -1;  1H NMR (300 MHz,  CDCl3 ) δ 5.91 (ddt, J = 
17.1, 10.3, 5.7 Hz, 1H), 5.63 (d, J = 9.2 Hz, 1H), 5.34 (dd, J = 17.2, 1.5 Hz, 1H), 5.26 (dd, J = 
10.3, 1.0 Hz, 1H), 4.82 (A of AB, d, J = 12.1 Hz, 1H), 4.71 (B of AB, d, J = 12.1 Hz, 1H), 4.62 
(d, J = 5.8 Hz, 2H), 4.46 (dd, J = 9.4, 1.1 Hz, 1H), 4.01 (dd, J = 6.5, 1.0 Hz, 1H), 1.84 (m, 1H), 
0.98 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.90 (s, 9H), 0.08 (s, 3H), -0.03 (s, 3H);  13C 
NMR (75 MHz,  CDCl3 ) δ 171.0, 154.5, 131.4, 118.9, 95.5, 77.2, 76.8, 74.6, 66.2, 55.9, 33.1, 
25.9, 19.2, 18.2, 18.0, -4.2, -4.8;  HRMS m/z calculated for C18H32O5N1Si1Cl3 [M+H]
+ 476.1188, 
476.1191 observed.   
 
 
[Compound 2-19]  A stirred solution of Pd(PPh3)4 (0.0764 grams, 0.066 mmol) in 1 mL of THF 
was cooled to -78°C.  To this was added n-BuLi (0.04 mL of a 1.6 molar solution in 
hexanes,0.064 mmol) and the solution was stirred at -78 for 1 hour at which time it was added to 
a separate stirred solution of compound 2-18 (0.3163 grams, 0.666 mmol) in 1 mL THF.  
Morpholine (0.57 mL, 6.6 mmol) was then immediately added to the reaction mixture.  The 
reaction was stirred at room temperature for 2 hours at which time the reaction was diluted with 
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15 mL of diethyl ether and organic layer washed with 1 M KHSO4 (3x15 mL) and brine(15 mL).  
The organic layer was dried over MgSO4 and concentrated to give 0.3226 grams of crude 
product mixture which was purified via flash chromatography (silica gel, 7:3 hexane: ethyl 
acetate) to give compound 2-19 (0.2490 grams, 86% yield) as a yellow oil.   
FTIR (neat) 3445, 3270, 3120, 2958, 2931, 2885, 2858, 1743 cm-1;  1H NMR (300 MHz,  CDCl3 
) δ 10.95 (s, 1H), 5.64 (d, J = 9.1 Hz, 1H), 4.85 (A of AB, d, J = 12.1 Hz, 1H), 4.70 (B of AB, d, 
J = 12.1 Hz, 1H), 4.48 (dd, J = 9.1, 1.5 Hz, 1H), 4.04 (dd, J = 6.6, 1.5 Hz, 1H), 1.97 – 1.80 (m, 
1H), 0.99 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.03 (s, 3H);  
13C NMR (75 MHz,  CDCl3 ) δ 177.2, 154.5, 95.3, 76.7, 74.6, 55.8, 32.9, 25.9, 19.1, 18.1, 18.1, -
4.3, -4.6;  HRMS m/z calculated for C15H28O5N1Si1Cl3 [M+H]
+ 436.0875, 436.0876 observed.   
 
 
[Compound 2-20] EDCI (0.0267 grams, 0.14 mmol) and 4-dimethylaminopyridine (0.0265 
grams, 0.22 mmol) were dissolved in CH2Cl2 (0.5 mL).  The solution was then added to a 
mixture of compound 2-19 (0.0515 grams, 0.12 mmol) and compound 2-15 (0.0875 grams, 0.30 
mmol) in a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room 
temperature and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed 
with a saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back 
extracted with CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and 
concentrated to give 0.1489 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 7:3 hexane: ethyl acetate) to give compound 2-20 (0.0542 grams, 
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65% yield) as yellow oil.  Because this reaction pathway was deemed unsuitable for future use 
compound 2-20 was not fully characterized but the proton NMR spectrum obtained is located in 
Appendix A. 
 
 
 [Compound 2-21]  A stirred solution of 8-(Boc-amino)octanoic acid (2.7442 grams, 10.58 
mmol) and 4-methylmorpholine (1.16 mL, 10.6 mmol) in 28mL of THF was cooled to -10°C.   
1.4mL of isobutyl chloroformate was added and the reaction was allowed to stir for 30 minutes.  
The reaction was allowed to warm to 0 ° C at which time a solution of the hydrochloride salt of 
compound 2-9 (2.9751 grams, 16.20 mmol) in 17mL of 1M NaOH was added.  The reaction was 
allowed to warm to room temperature and stir for 24 hours at which time it was diluted with H2O 
(50 mL).  The layers were separated and the aqueous layer was washed with ethyl acetate (2x50 
mL).  The combined organic layers were then extracted with saturated NaHCO3 solution (3x50 
mL).  All aqueous layers were combined and acidified to pH=2 with 1 M hydrochloric acid and 
extracted with ethyl acetate (3x100 mL).  The combined extractions were then dried over 
MgSO4, and concentrated to give compound 2-21 (3.3533 grams, 82% yield) as a yellow 
foaming oil which was used without further purification.   
FTIR (neat) 3374, 2932, 2860, 1702, 1655, 1528, 1366, 1275, 1252, 1171 cm-1;  1H NMR (300 
MHz,  CDCl3 ) δ 7.11 (d, J=8.8 Hz, 1H), 4.79 (d, J=9.4 Hz, 1H), 3.80 (d, J=9.4 Hz, 1H), 3.07 
(br, 2H), 2.17 - 2.40 (m, 2H), 1.54 - 1.85 (m, 3H), 1.18 - 1.53 (m, 17H), 1.02 (d, J=6.4 Hz, 3H), 
0.90 (d, J=6.4 Hz, 3H);  13C NMR (75 MHz,  CDCl3 ) δ 177.3, 174.5, 156.1, 78.9, 77.2, 54.3, 
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40.2, 35.8, 33.8, 30.7, 29.5, 28.6, 28.5, 28.1, 26.2, 25.3, 24.4, 19.0, 18.7;  HRMS m/z calculated 
for C19H36O6N2  [M+Na]
+ 411.2466, 411.2468 observed . 
 
 
[Compound 2-22] Allyl bromide (4.60 mL, 53.2 mmol) was added to a stirred solution of 
compound 2-21 (2.3607 grams, 6.08 mmol) and NaHCO3 (2.1974 grams, 26.16 mmol) in 30mL 
of DMF.  The reaction was stirred for 48 hours at which time it was diluted with H2O (50 mL).  
The aqueous layer was extracted with ethyl acetate (3x75 mL).  The combined organic layers 
were then washed with H2O (2x50 mL), dried over MgSO4, and concentrated to give 2.5233 
grams of crude product mixture which was purified via flash chromatography (silica gel, 1:1 
hexane: ethyl acetate) to give compound 2-22 (1.9933 grams, 77% yield) as colorless oil.   
FTIR (neat) 3346, 2931, 2858, 1743, 1692, 1660, 1530, 1366, 1252, 1172 cm-1;  1H NMR (300 
MHz, CDCl3) δ 6.75 (d, J=9.4 Hz, 1H), 5.78 (ddt, J=17.2, 10.4, 5.7 Hz, 1H), 5.20 (dd, J=17.0, 
1.2 Hz, 1H), 5.11 (dd, J=10.6, 1.2 Hz, 1H), 4.69 (dd, J=9.1, 2.1 Hz, 1H), 4.51 (d, J=5.3 Hz, 2H), 
3.61 (dd, J=9.4, 1.8 Hz, 1H), 2.96 (dd, J=5.9 Hz, 2H), 2.14 (t, J=7.3 Hz, 2H), 1.42 - 1.70 (m, 
4H), 1.31 (s, 9H), 1.30 (br, 2H), 1.20 (br, 6H), 0.89 (d, J=7.0 Hz, 3H), 0.79 (d, J=7.0 Hz, 3H) 13C 
NMR (75 MHz,  CDCl3 ) δ 173.6, 171.1, 156.0, 131.5, 118.1, 78.7, 76.9, 65.6, 54.4, 40.2, 36.0, 
31.0, 29.6, 28.7, 28.6, 28.1, 26.3, 25.2, 18.9, 18.7;  HRMS m/z calculated for C22H40O6N2  
[M+Na]+ 451.2779, observed 451.2771.   
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[Compound 2-23]  EDCI (0.1921 grams, 1.01 mmol) and 4-dimethylaminopyridine (0.2093 
grams, 1.71 mmol) were dissolved in CH2Cl2 (5 mL).  The solution was then added to a mixture 
of compound 2-19 (0.3233 grams, 0.74 mmol) and compound 2-22 (0.3540 grams, 0.83 mmol) 
in a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room 
temperature and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed 
with a saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back 
extracted with CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and 
concentrated to give 0.9507 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 1:1 hexane: ethyl acetate) to give compound 2-23 (0.3712 grams, 
59% yield) as yellow oil.   
FTIR (neat) 3444, 3359, 2963, 2932, 2881, 2858, 1748, 1722, 1504, 1367, 1253, 1165 cm-1;  1H 
NMR (300 MHz,  CDCl3 ) δ 6.36 (d, J=8.8 Hz, 1H), 5.90 (ddt, J=16.9, 10.7, 5.9 Hz, 1H), 5.71 
(d, J=7.6 Hz, 1H), 5.32 (dd, J=17.3, 1.5 Hz, 1H), 5.24 (dd, J=10.0, 1.2 Hz, 1H), 4.99 (d, J=8.8 
Hz, 2H), 4.83 (A of AB d, J=12.3 Hz, 1H), 4.68 (B of AB d, J=12.3 Hz, 1H), 4.58 (d, J=5.9 Hz, 
2H), 4.55 (br, 1H), 4.25 (dd, J=7.9, 2.6 Hz, 1H), 3.88 (dd, J=4.7, 2.9 Hz, 1H), 3.09 (d, J=6.7 Hz, 
2H), 2.14 (t, J=7.8 Hz, 2H), 1.71 - 2.09 (br m, 4H), 1.54 - 1.71 (m, 2H), 1.44 (s, 9H), 1.33 (br, 
6H), 0.80 - 1.09 (m, 21H), 0.09 (s, 3H), 0.06 (s, 3H);  13C NMR (75 MHz,  CDCl3 ) δ 173.4, 
170.6, 169.9, 155.8, 154.3, 131.6, 118.6, 95.2, 79.6, 78.7, 75.1, 74.5, 66.3, 55.2, 52.0, 40.4, 36.1, 
33.3, 29.8, 29.7, 29.0, 28.8, 28.3, 26.5, 25.7, 25.3, 18.8, 18.3, 18.1, 17.8, 17.7, -4.4, -4.6;  HRMS 
m/z calculated for C37H66O10N3Si1Cl3 [M+Na]
+ 870.3455, 870.3458 observed.    
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[Compound 2-23a]  Compound 2-23 (0.1947 grams, 0.23 mmol) was dissolved in acetic 
anhydride (2.80 mL, 29.7 mmol) and added via syringe to a flask charged with freshly activated 
Zinc10 (0.3691 grams, 5.64 mmol).  To this was added triethylamine (0.06 mL, 0.43 mmol).  This 
reaction mixture was sonnicated at 0 C for four hours after which the reaction contents were 
diluted with methanol (50 mL) and filtered to remove solid.  The filtrate was then concentrated 
(temperature should not exceed 40 C to help prevent racemization), dissolved in methanol (50 
mL) then concentrated again.  This process was repeated three times to help remove excess 
acetic anhydride.  The final concentration yielded 0.3779 grams of crude product mixture which 
was purified via flash chromatography (silica gel, 1:1 hexane: ethyl acetate) to give compound 2-
23a (0.0935 grams, 57% yield) as a yellow oil.   
FTIR (neat)  3436, 2962, 2930, 2856, 1746, 1661, 1536 cm-1;  1H NMR (300 MHz,  CDCl3 ) δ 
6.68 (d, J=9.4 Hz, 1H), 6.21 (d, J=7.6 Hz, 1H), 5.90 (ddt, J=17.0, 10.7, 5.9Hz, 1H), 5.32 (dd, 
J=17.3, 1.5 Hz, 1H), 5.23 (dd, J=10.5, 1.2 Hz, 1H), 4.98 (dd, J=10.0, 1.8 Hz, 1H), 4.93 (dd, 
J=8.5, 2.1 Hz, 1H), 4.48 - 4.70 (m, 2 H), 4.55 (br, 1H), 4.44 (dd, J=7.3, 2.6 Hz, 1H), 3.88 (dd, 
J=4.39, 2.63 Hz, 1H), 3.09 (dd, J=9.4, 6.4 Hz, 2H), 2.33 (t, J=7.6 Hz, 2H), 2.03 (s, 3H), 1.94 (m, 
1H), 1.72 - 1.86 (m, 1H), 1.66 (t, J=7.03 Hz, 2H), 1.44 (s, 9H), 1.19 - 1.44 (m, 8H), 0.84 - 1.11 
(m, 21H), 0.09 (s, 3H), 0.05 (s, 3H);  13C NMR (75 MHz,  CDCl3 ) δ 173.7, 170.9, 170.3, 170.2, 
155.9, 131.8, 118.5, 79.5, 78.9, 75.0, 66.3, 53.4, 52.0, 40.5, 36.1, 33.6, 29.9, 29.7, 29.01, 28.95, 
28.4, 26.6, 25.9, 25.4, 23.2, 18.9, 18.4, 18.2, 17.9, 17.7, -4.4, -4.5;  HRMS m/z calculated for 
C36H67O9N3Si1 [M+Na]
+ 736.4539, 736.4549 observed.    
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[Compound 2-24]  A solution of compound 2-23a (0.1222 grams, 0.17 mmol) dissolved in THF 
(4 mL) was cooled to 0 C.  To this solution was added a 1 M solution of tetra-n-
butylammonium fluoride (0.52 mL, 0.52 mmol).  The reaction mixture was stirred at 0 C for 
30 minutes after which the contents were poured into a saturated solution of ammonium chloride 
(25 mL).  The aqueous layer was extracted with ethyl acetate (3x 30 mL).  The combined organic 
layers were washed with water (2x 20 mL), a brine solution (20 mL), dried over MgSO4, and 
concentrated to give 0.1032 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 3:7 hexane: ethyl acetate) to give compound 2-24 (0.0847 grams, 
83% yield) as a clear oil.   
FTIR (neat) 3321, 2966, 2933, 2874, 2859, 1744, 1664, 1534, 1465, 1391, 1367, 1276, 1250, 
1171, 733 cm-1;  1H NMR (300 MHz,  CDCl3 ) δ 6.70 (d, J=8.8 Hz, 1H), 6.62 (d, J=8.8 Hz, 1H), 
5.80 - 6.04 (ddt, J=17.0, 10.7, 5.8Hz, 1H), 5.36 (dd, J=17.0, 1.2 Hz, 1H), 5.28 (dd, J=10.6, 1.2 
Hz, 1H), 5.02 (dd, J=8.8, 1.8 Hz, 1H), 4.96 (d, J=9.4 Hz, 1H), 4.64 - 4.78 (m, 2H), 4.60 (dd, 
J=7.9, 6.7 Hz, 2H), 3.61 (d, J=8.2 Hz, 1H), 3.12 (d, J=6.45 Hz, 2H), 2.19 - 2.36 (m, 2H), 2.05 (s, 
3H), 1.82 - 2.00 (m, 1H), 1.56 - 1.80 (m, 3H), 1.44 (s, 9H), 1.26 - 1.55 (m, 8H), 1.02 (t, J=7.03 
Hz, 6H), 0.92 (d, J=6.45 Hz, 6H);  13C NMR (75 MHz,  CDCl3 ) δ 173.6, 171.4, 171.0, 170.6, 
156.0, 131.2, 119.0, 79.1, 78.9, 76.8, 66.7, 54.8, 52.2, 40.3, 35.8, 30.6, 29.8, 29.4, 28.7, 28.6, 
28.3, 26.3, 25.1, 22.8, 18.9, 18.8, 18.7, 18.3;  HRMS m/z calculated for C30H53O9N3 [M+Na]
+ 
622.3674, 622.3675 observed.    
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[Compound 2-25]  Trifluoroacetic acid (6 mL) was added to a stirred solution of compound 2-
24 (0.2383 grams, 0.40 mmol) in CH2Cl2 (9 mL).  Reaction was stirred at room temperature for 3 
hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in diethyl ether and concentrated three times to ensure all trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
The acid protected amine and compound 2-8 (0.1225 grams, 0.40 mmol) were dissolved in DMF 
(1.5 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (0.20 mL, 1.2 mmol) was added to 
the reaction mixture followed by 1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate or COMU (0.1703 grams,0.40 mmol) dissolved in 
DMF (1 mL).  The reaction was stirred at 0 oC and allowed to warm to room temperature 
overnight.  After 24 hours the reaction mixture was diluted with ethyl acetate (40 mL).  The 
organic layer was then washed with 1 M hydrochloric acid (2x20 mL), saturated NaHCO3 
solution (2x20 mL), and brine (2x20 mL).  The organic layer was dried over MgSO4 and 
concentrated to give 0.2885 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 100% ethyl acetate) to give compound 2-25 (0.1729 grams, 55% 
yield over 2 steps) as a yellow oil.   
FTIR (neat) 3301, 2083, 2032, 2963, 2933, 2874, 2858, 1747, 1658, 1547, 1373, 1241, 1179, 733 
cm-1; 1H NMR (300 MHz,  CDCl3 ) δ 7.13 - 7.41 (m, 5H), 7.04 (t, J=5.86 Hz, 1H), 6.66 (d, J=7.0 
Hz, 1H), 6.63 (d, J=7.6 Hz, 1H), 6.38 (d, J=5.3 Hz, 1H), 5.92 (ddt, J=17.0, 10.8, 6.8 Hz, 1H), 
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5.30 - 5.46 (m, 3H), 5.27 (dd, J=10.5, 1.2 Hz, 1H), 4.90 - 5.08 (m, 4H), 4.69 (dd, J=8.5, 1.5 Hz, 
1H), 4.59 (t, J=6.2 Hz, 2H), 4.25 (q, J=6.4 Hz, 1H), 3.50 - 3.72 (m, 1H), 3.40 (dd, J=14.6, 3.5 
Hz, 1H), 3.12 - 3.33 (m, 2H), 3.02 (dd, J=14.6, 9.4 Hz, 1H), 2.12 - 2.35 (m, 4H), 2.05 (s, 3H), 
1.97 (s, 3H), 1.91 (m, 1H), 1.56 - 1.79 (m, 3H), 1.42 - 1.55 (m, 2H), 1.12 - 1.41 (m, 6H), 1.03 (d, 
J=7.0 Hz, 3H), 1.01 (d, J=7.0 Hz, 3H), 0.91 (dd, J=7.0, 1.2 Hz, 6H);  13C NMR (75 MHz,  
CDCl3 ) δ 173.7, 171.5, 171.4, 171.2, 171.0, 170.6, 168.9, 136.4, 131.5, 131.3, 129.3, 128.3, 
126.8, 119.5, 119.1, 79.2, 76.9, 75.1, 66.8, 54.8, 52.8, 52.2, 39.1, 37.7, 35.9, 34.8, 30.7, 29.5, 
28.8, 28.6, 28.2, 25.9, 25.0, 22.9, 22.5, 19.0, 18.9, 18.7, 18.3;  HRMS m/z calculated for 
C41H62O11N4 [M+Na]
+ 809.4307, 809.4303 observed.   
  
 
[Compound 2 WU-07047]  A solution of Grubbs 2nd generation catalyst (0.0241 grams, 0.028 
mmol) dissolved in CH2Cl2 (5 mL) was added to a stirred and refluxing solution of compound 2-
25 (0.1070 grams, 0.14 mmol) in CH2Cl2 (100 mL).  The reaction was refluxed for 24 hours at 
which time the reaction contents were concentrated.  The crude product mixture was purified via 
flash chromatography (silica gel, 100% ethyl acetate) to give the trans alkene isomer (shown 
below) compound WU-07047 (0.0790 grams, 77% yield) as a brown oil.   
FTIR (neat) 3299, 3065, 2963, 2934, 2874, 1749, 1657, 1545, 1374, 1238, 1200 cm-1;  1H NMR 
(300 MHz,  CDCl3 ) δ 7.13 - 7.43 (m, 6H), 6.91 (t, J=5.6 Hz, 1H), 6.73 (d, J=8.2 Hz, 1H), 6.60 
(d, J=8.8 Hz, 1H), 5.17 - 5.49 (m, 1H), 4.87 - 5.12 (m, 2H), 4.57 - 4.82 (m, 4H), 4.49 (dd, 
J=14.1, 4.7 Hz, 1H), 4.13 (d, J=5.3 Hz, 1H), 3.59 - 3.77 (m, 1H), 3.13 - 3.35 (m, 3H), 2.94 - 3.08 
OH O
NHAc
O
O
HN
O
O
N
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NHAc
O O
O
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(m, 1H), 2.18 - 2.46 (m, 2H), 1.86 - 2.15 (m, 2H), 2.09 (s, 3H), 2.04 (s, 3H), 1.16 - 1.84 (m, 
12H), 0.72 - 1.15 (m, 12H);  13C NMR (75 MHz,  CDCl3 ) δ 175.0, 171.2, 171.0, 170.6, 170.5, 
170.2, 169.5, 136.8, 129.4, 128.3, 127.0, 126.8, 125.7, 77.7, 77.0, 76.1, 64.3, 55.0, 52.7, 52.0, 
38.9, 37.7, 35.1, 34.2, 30.9, 29.5, 28.1, 27.04, 26.95, 24.0, 22.9, 22.6, 22.5, 19.1, 18.9, 18.7, 
18.2;  HRMS m/z calculated for C39H58O11N4 [M+Na]
+ 781.3994, 781.3992 observed.      
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CHAPTER THREE 
BRINGING COMPLEXITY BACK TO THE TOP 
BRIDGE 
3.1 What is the Next Step? 
 After the promising initial results for WU-07047 were obtained, we wanted to build on 
that success by obtaining the best core scaffold for our molecule possible.  The goal was to find 
the minimum core structure needed to optimize the affinity of the analog while still maintaining 
the relative ease of synthesis of the WU-07047 molecule.  Since the WU-07047 maintains the 
complexity of the YM molecule’s right and left side, to increase the potency of the molecule I 
proposed changing the top bridge.  This decision was made by again studying the YM-Gq bound 
crystal structure (Figure 2.1 and 3.1).1 
Figure 3.1: New Protecting Group Plan 
 
When we synthesized WU-07047 we maintained all of the main binding interactions 
between the G protein and YM molecule but left out an intramolecular hydrogen bond.1  This 
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hydrogen bond is between the atoms labeled with 1’s in Figure 3.1.  This hydrogen bond has 
been proposed as an interaction that stabilizes the bound conformation of YM. Hence, we 
thought that reintroducing the hydrogen bond donating amide into the top bridge of the molecule 
might improve the activity of the simplified analog. With this in mind, I suggested two new 
target molecules (Figure 3.2).  The first molecule would have the entire YM top bridge intact 
(Figure 3.2A).  This molecule is more complicated than what is needed to prove the importance 
of the intramolecular hydrogen bond, but in the future we could use molecule 3.2A as a step 
towards making the natural product, YM.  If we made the complete YM molecule, we could then 
use it as a positive control to gauge the relative activity of our simplified analogs in biological 
assays.  It is important to note that the proposed top chain does not include the dehydroalanine 
present in the YM molecule.  Since these groups are very susceptible to nucleophilic attack we 
wanted a more stabile group present.  We decided to replace the dehydroalanine with an N-
methyl-D-alanine.  We knew we needed this specific enantiomer of N-methyl-alanine after 
studying a literature report that tested basic variations of the YM molecule.2  In this paper, the 
authors wanted to see if the dehydroalanine was actually necessary for activity.  They performed 
a simple hydrogenation on the YM molecule and found that the D-alanine that resulted from 
hydrogenation had the same IC50 values as YM while the L-alanine had significantly reduced 
activity.2 
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Figure 3.2: New Target Molecules 
 
The second possible molecule suggested (Figure 3.2B) contains a more simplified core 
scaffold than molecule 3.2A.  In molecule 3.2B the top bridge is still a relatively simplified alkyl 
chain but it contains the extra amide bond needed for the proposed intramolecular hydrogen 
bond.  When making a final decision I thought about what would yield the best results for the 
future of the project and I decided on pursuing molecule 3.2A.  The way in which I would make 
either molecule would follow the same synthetic scheme as WU-07047 with the only change 
being the slightly more complicated bridge in 3.2A. Both cases would build the β-
hydroxyleucine monomer derivative highlighted in red with the rest of the molecule being added 
in during subsequent synthetic steps. The β-hydroxyleucine monomer piece needed for 3.2B 
could be envisioned as taking 3 steps to complete using chemistry developed previously, while 
corresponding piece in 3.2A would only take one additional peptide coupling for a 4-step 
synthesis.  With this in mind,  the synthesis of the 3.2A was undertaken with the possibility of 
switching to the easier molecule if unforeseen complications arose. 
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3.2 Synthesis of β-Hydroxyleucine Monomer 3.2A 
 The retrosynthetic analysis of the target molecule follows the same basic pathway used 
for WU-07047 (Figure 3.3).  The final steps in the synthesis involve the same between the β-
hydroxyleucine dimer and molecule 2-8 and a subsequent ring closing metathesis reaction.  The 
β-hydroxyleucine dimer can be broken down into the two monomer units 2-19 and piece B.  All 
reactions from the synthesis of the β-hydroxyleucine dimer to the finished molecule are the same 
as WU-07047.  Piece B is the major difference in construction, although we planned to put it 
together using similar chemistry to 2-22 from the previous section.  We wanted to try and put 
together the three amino acid top bridge before the subsequent esterification reaction since the 
esterification reaction had proven so difficult before.  We did not want a low yielding reaction 
followed by multiple peptide bond formations.  It was with these factors in mind that we went 
after piece B. 
Figure 3.3: Retrosynthetic Analysis 
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 We started the synthesis by combining compound 2-9 and Boc-N-methy-L-alanine using 
the same mixed anhydride reaction used to form compound 2-21 in the WU-07047 synthesis. In 
this case, the yield of the coupling reaction was markedly worse. The product was obtained in 
only 18-39% yield (Scheme 3.1).  What’s more, the subsequent allyl protection of the acid group 
proceeded with a reproducible, yet ineffective 50% yield.  The reason for these differences in 
yield could be due to the very different steric properties of the new amino acid used as compared 
to the long alkyl chain used previously, as well as possible solubility differences in the products 
formed making isolation more difficult. 
Scheme 3.1: Mixed Anhydride Peptide Coupling 
 
 We decided to sidestep the inefficiencies of the reactions by using a slightly altered route.  
We started with the Boc and allyl-protected β-hydroxyleucine monomer 2-15 and deprotected the 
Boc protecting group using trifluoroacetic acid.  The acid protected amine was then combined 
with Boc-N-methy-L-alanine in a COMU coupling reaction to give compound 3-2 for a much 
improved 85% yield (Scheme 3.2).  Even though this reaction pathway takes one additional step 
the overall yield is 67% as opposed to a 20% yield using the 2-step synthesis presented in 
Scheme 3.1.  The peptide top bridge elongation was then continued using the same TFA 
deprotection/COMU coupling protocol.  Compound 3-3 was completed in a 73% yield, but the 
subsequent coupling to obtain compound 3-4 was problematic. The yield of the crude product 
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was 73%, but only 31% of the purified product was obtained after column chromatography.  This 
was confusing because the spectrum of the crude material showed almost all product with very 
minor impurities present (Figure 3.4).  We propose that there is a possible degradation of the 
product on the column that is leading to the low isolated yields.  We noticed these problems most 
prominently with synthesis of compound 3-4 but observed similar, yet less dramatic, 
inconsistencies between crude and isolated yields for compounds 3-2 and 3-3.  Because of this 
and the fact that the spectra of the crude reaction products were so clean we decided to cut out 
column purification from compound 3-2 to 3-4.     
Scheme 3.2: Top Bridge Synthesis 
 
 
 
 
 68
Figure 3.4A: Crude Spectrum of Compound 3-4 
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Figure 3.4B: Purified Spectrum of Compound 3-4 
DTR_08_045_column_product.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
OH
NH
O
O
O N
O
NH
O NBoc
Purified
 
 After compound 3-4 was synthesized the penultimate esterification reaction was 
attempted to no avail.  When the optimized Steglich esterification reaction conditions used to 
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synthesize WU-07047 were used to combine alcohol 3-4 and acid 2-19 much lower yields were 
obtained.  In the very best case, we were only able to obtain the β-hydroxyleucine dimer 3-5 in a 
yield of 20% (Scheme 3.3).  In most attempts to complete this esterification, less than 5% of the 
desired product was obtained.  The reason for the lower yields was not immediately apparent to 
us. However, it was clear that use of the complete top bridge would not be a viable alternative for 
the future of the project. Not only were the yields of the reactions involving the complete top 
bridge lower, but the characterization of the molecule was much more difficult using simple 
proton NMR.  The rotamers that appear in the proton spectra when methylated amides are 
present in the sample split the proton signals for one molecule into multiple peaks.  These 
rotamers can be simplified, collapsing multiple rotamer peaks into single molecule, by changing 
the NMR solvent from CDCl3 to DMSO (compound 3-3 presented in Figure 3.5). Unfortunately, 
getting the compound back out of DMSO is impossible without a separate column separation. 
These factors made the complete top bridge molecule untenable for a base molecule, but in the 
future a brute force effort could be taken to try and obtain the YM natural product using the 
procedures outlined.   
Scheme 3.3: Steglich Esterification Reaction 
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Figure 3.5A: Proton NMR Spectrum of Compound 3-3 in CDCl3 
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Figure 3.5B: Proton NMR Spectrum of Compound 3-3 in DMSO 
DTR_08_013_product_inDMSO.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0.05
0.10
0.15
0.20
0.25
0.30
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y OH
NH
O
O
O N
O
NH
O
O
 
 71
3.3 Esterification Test Study  
While it was becoming clear that the synthesis of the more complicated β-hydroxyleucine 
monomer 3.2A was difficult in its own right (complicated by the key esterification reaction 
needed for assembling the targeted analog) and inconsistent with a versatile base structure for 
building analogs, it was also clear that understanding why the complexity of the bridge caused 
these complications was important for understanding past efforts and planning for the future. 
Why do the amino acids in the top bridge complicate the subsequent reactions?  The desire to 
answer this question was fueled by two other papers published in this area including a synthesis 
that was published concurrently with our WU-07047 synthesis.   
 When the Yamanouchi Pharmaceutical Company first discovered YM-254890 they 
published a very insightful paper on different simple YM analogs and their relative biological 
activity in comparison to YM.2  These compounds were either isolated during the purification 
process of YM-254890 from Chromobacterium sp. QS3666 or obtained via simple chemistry 
(An example of this is the hydrogenation of the dehydroalanine amino acid of the YM molecule 
mentioned previously).3  It is because of this we know of the YM-280193 molecule (presented in 
Figure 3.6).2  This molecule has the same core ring structure of YM-254890 but is lacking the β-
hydroxyleucine side chain.  In this study they found that YM-280193 is approximately 40 times 
less potent than YM-254890.2  
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Figure 3.6: YM Analog Without Second β−Hydroxyleucine Monomer2 
 
 It was because of this known lower activity that we were very surprised to find a paper 
published concurrently with our WU-07047 paper outlining the synthesis of YM-280193.4  We 
already know that YM is extremely difficult to synthesize5 so it was nice to see someone almost 
complete the molecule, but I was curious as to why after getting so close the authors did not take 
the additional 2-3 synthesis steps to finish the full YM-254890 molecule.  The authors did 
mention at the end of the paper that they envisioned an esterification reaction to reach the target 
molecule, yet did not actually complete the esterification.  This fact along with the similar 
trouble that I had making the molecule outlined in section 3.2 led me to believe that this 
esterification reaction, like in the simplified molecule, is the limiting step in the YM analog 
synthesis field and therefore would be worth exploring in more detail.  So why does changing the 
top bridge affect both the viability of the esterification reaction at a base level and the stability of 
the products formed?  
 I decided to use three different test molecules to address this question (Scheme 3.5).  The 
first test molecule 3-2 has the full Boc-N-methyl-L-alanine found in the more complex bridge 
and would be the most sterically hindered molecule used.  To see if taking away some of this 
steric bulk might improve the reaction a separate molecule 3-6 was synthesized (Scheme 3.4).  
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This molecule was made in a similar way as 3-2 but with Boc-N-methyl-glycine as the amino 
acid.  The last molecule used was control compound 2-22.  This molecule is one that we had 
successfully used in the coupling reaction before. If it still worked, then we could rule out any 
sort of possible issues with reactants and other starting materials.  All reactants (EDC and 
DMAP) were bought fresh for the study, and all compounds  (3-2, 3-6, 2-22, and 2-19) were 
synthesized within a month period to ensure minimal degradation occurred prior to the study.  
Finally all three tests were done within a two week period to ensure all reaction conditions were 
the same and as many variables as possible could be eliminated.  
Scheme 3.4: Compound 3-6 Synthesis 
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Scheme 3.5: Test Substrate Synthesis and Esterification Reactions 
 
 The first two test pathways, labeled as A and B in Scheme 3.5, demonstrated how much 
changing the complexity of the amino acid in question affected the esterification reaction.  In test 
study A, the reaction ran in a 16% yield of the target compound 3-7 with 22% recovered alcohol 
starting material.  The major side product obtained was one that I was not expecting and that was 
the product with the acid instead of the protected ally ester.  This was isolated in 23% yield.  I 
had encountered what I thought was this type of product before when making compound 3-5 but 
had not been able to gather definitive evidence for it.  What was even more peculiar is that 
during column purification of the crude reaction mixture a solid was isolated from the top of the 
silica plug. When a proton NMR spectrum of this molecule was obtained, it was revealed to be 
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the allyl-protected DMAP compound (presented in Figure 3.7).  Something about the presence of 
the alanine seems to make the allyl ester more labile.  I noticed this in later reactions as well.   
Figure 3.7: Allyl Protected DMAP 
 
 For test reaction B, I was able to obtain better overall results with a 37% yield of the 
target compound 3-8 and 48% recovered alcohol starting material.  This was a significant 
improvement, but the reaction also afforded an elimination product from either compound 3-8 or 
possibly compound 3-6.  Even though the elimination product was only isolated in a 6% yield, I 
knew that I had seen this type of side product before.  To my surprise, when looking through old 
lab notebook entries I found that I had run test reaction A before and found that in that test 
reaction a large amount of elimination product was obtained.   
 This prior test reaction was run using the same conditions as the ones described above 
(Scheme 3.6). In this case, the crude reaction mixture contained both the product (integration on 
left which corresponds to the proton labeled as 1) and the starting alcohol (integration on right 
which corresponds to the proton labeled as 2) (Figure 3.8A).  We know that proton 1 is not from 
the starting acid because the alkaline workup for the reaction eliminates any acid from the crude 
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mixture.  So besides some other solvent or DMAP impurities, the crude mixture contains a 
0.80:1 mixture of product to starting alcohol with none of the elimination product.  After silica 
gel chromatography was performed, no product was obtained.  Instead the elimination product 
shown in Figure 3.8B was obtained along with the starting alcohol (not shown).  The ratio of 
elimination product to starting alcohol obtained after the column was 0.85:1.  Clearly, the 
product underwent the elimination reaction during the purification step. The yields from this 
reaction, as well as the recovered starting material are consistent with test case A from Scheme 
3.5. We have found that the elimination reaction does not occur consistently. Sometimes it does 
not happen, and sometimes it destroys all the product present.  The reasons for this inconsistency 
are not clear at this point, but the fact that the elimination happens sometimes is very problematic 
for this reaction pathway.  
Scheme 3.6: Test Esterification A From Earlier 
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Figure 3.8A: Test Esterification A Crude Spectrum 
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Figure 3.8B: Test Esterification A Elimination After Column 
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 Finally, when the control reaction labeled C in Scheme 3.5 was performed, it worked 
better than it had previously leading to a 63% yield of the coupled product along with 23% of the 
recovered alcohol starting material.  So the control reaction proceeded much better than either 
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test cases A and B with respect to both yield and mass balance.  This proved that the simplified 
top bridge with no amino acid connected directly to the β-hydroxyleucine was very beneficial for 
the esterification reaction. While it is not clear whether the amino acid at this position interferes 
with the esterification reaction by steric (the extra methyl group in the alanine derivative), 
inductive (the electron-withdrawing effect of the C-N bond in the added amino acid), or both, it 
is clear that new analogs built in the future will benefit from not having an amino acid in this 
position.  This fact led us to the decision that we would pursue our secondary target molecule B 
from Figure 3.2.     
 
3.4 Experimental Procedures for Chapter Three Compounds 
 
[Compound 3-1] A stirred solution of Boc-N-methyl-L-alanine (1.8896 grams, 9.30 mmol) and 
4-methylmorpholine (1.01 mL, 9.19 mmol) in 25mL of THF was cooled to -10°C.  Isobutyl 
chloroformate (1.21 mL, 9.26 mmol) was added and the reaction was allowed to stir for 30 
minutes.  The reaction was allowed to warm to 0 ° C at which time a solution of the 
hydrochloride salt of compound 2-9 (2.5424 grams, 13.85 mmol) in 13 mL of 1M NaOH was 
added.  The reaction was allowed to warm to room temperature and stir for 24 hours at which 
time it was diluted with H2O (50 mL).  The layers were separated and the aqueous layer was 
washed with ethyl acetate (2x50 mL).  The combined organic layers were then extracted with 
saturated NaHCO3 solution (3x50 mL).  All aqueous layers were combined and acidified to 
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pH=2 with 1 M hydrochloric acid and extracted with ethyl acetate (3x100 mL).  The combined 
extractions were then dried over MgSO4, and concentrated to give compound 3-1 (1.2032 grams, 
39% yield) as a yellow foaming oil which was used without further purification.  Because this 
reaction pathway was deemed unsuitable for future use compound 3-1 was not fully 
characterized but the proton NMR spectrum obtained is located in Appendix A. 
 
 
[Compound 3-2] Trifluoroacetic acid (40 mL) was added to a stirred solution of compound 2-15 
(1.9190 grams, 6.68 mmol) in CH2Cl2 (50 mL).  The reaction was stirred at room temperature for 
3 hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane (40 mL) and concentrated (three times) to ensure all trifluoracetic 
acid was removed.  The crude acid protected amine product was used in the next reaction 
without further purification.   
The acid protected amine and Boc-N-methyl-L-alanine (1.0500 grams, 5.17 mmol) were 
dissolved in DMF (75 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (3.50 mL, 20.7 
mmol) was added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(2.2321 grams, 5.21 mmol) dissolved in DMF (5 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (100 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x50 mL), saturated NaHCO3 solution (2x50 mL), and brine (2x50 mL).  The organic layer was 
OH
OAllyl
O
HN
O NBOC
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dried over MgSO4 and concentrated to give 2.1787 grams of crude product mixture which was 
purified via flash chromatography (silica gel, 1:1 hexane: ethyl acetate) to give compound 3-2 
(1.6438 grams, 85% yield over 2 steps) as a yellow oil.  Because this reaction pathway was 
deemed unsuitable for future use compound 3-2 was not fully characterized but the proton NMR 
spectrum obtained is located in Appendix A. 
 
 
[Compound 3-3] Trifluoroacetic acid (15 mL) was added to a stirred solution of compound 3-2 
(1.1980 grams, 3.22 mmol) in CH2Cl2 (22 mL).  The reaction was stirred at room temperature for 
3 hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane (40 mL) and concentrated (three times) to ensure all trifluoracetic 
acid was removed.  The crude acid protected amine product was used in the next reaction 
without further purification.   
The acid protected amine and Boc-L-alanine (0.6124 grams, 3.24 mmol) were dissolved 
in DMF (45 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (1.60 mL, 9.48 mmol) was 
added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(1.3892 grams, 3.25 mmol) dissolved in DMF (5 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (100 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x50 mL), saturated NaHCO3 solution (2x50 mL), and brine (2x50 mL).  The organic layer was 
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dried over MgSO4 and concentrated to give 1.6363 grams of crude product mixture which was 
purified via flash chromatography (silica gel, 3:7 hexane: ethyl acetate) to give compound 3-3 
(1.0385 grams, 73% yield over 2 steps) as a yellow oil.  Because this reaction pathway was 
deemed unsuitable for future use compound 3-3 was not fully characterized but the proton NMR 
spectrum obtained is located in Appendix A. 
 
[Compound 3-4] Trifluoroacetic acid (2 mL) was added to a stirred solution of compound 3-3 
(0.0320 grams, 0.07 mmol) in CH2Cl2 (3 mL).  The reaction was stirred at room temperature for 
3 hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane (10 mL) and concentrated (three times) to ensure all trifluoracetic 
acid was removed.  The crude acid protected amine product was used in the next reaction 
without further purification.   
The acid protected amine and Boc-N-Me-D-alanine (0.0155 grams, 0.08 mmol) were 
dissolved in DMF (1 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (0.04 mL, 0.2 
mmol) was added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(0.0331 grams, 0.08 mmol) dissolved in DMF (0.8 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (25 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x15 mL), saturated NaHCO3 solution (2x15 mL), and brine (2x15 mL).  The organic layer was 
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dried over MgSO4 and concentrated to give 0.0277 grams of crude product mixture (73% crude 
yield) which was purified via flash chromatography (silica gel, ethyl acetate) to give compound 
3-4 (0.0118 grams, 31% yield over 2 steps) as a yellow oil.  Because this reaction pathway was 
deemed unsuitable for future use compound 3-4 was not fully characterized but the proton NMR 
spectrum obtained is located in Appendix A. 
 
[Compound 3-5] EDCI (0.0568 grams, 0.30 mmol) and 4-dimethylaminopyridine (0.0666 
grams, 0.55 mmol) were dissolved in CH2Cl2 (1 mL).  The solution was then added to a mixture 
of compound 2-19 (0.1044 grams, 0.24 mmol) and compound 3-4 (0.1281 grams, 0.24 mmol) in 
a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room temperature 
and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed with a 
saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back extracted with 
CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and concentrated to 
give 0.2660 grams of crude product mixture which was purified via flash chromatography (silica 
gel, ethyl acetate) to give compound 3-5 (0.0445 grams, 20% yield) as yellow oil.  Because this 
reaction pathway was deemed unsuitable for future use compound 3-5 was not fully 
characterized but the proton NMR spectrum obtained is located in Appendix A. 
 
 83
 
[Compound 3-6] Trifluoroacetic acid (6 mL) was added to a stirred solution of compound 2-15 
(0.3884 grams, 1.35 mmol) in CH2Cl2 (9 mL).  Reaction was stirred at room temperature for 3 
hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane and concentrated three times.  The crude material was then 
dissolved in diethyl ether and concentrated once to ensure all the trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
The acid protected amine and Boc-N-methylglycine (0.2338 grams, 1.24 mmol) were 
dissolved in DMF (4 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (0.83 mL, 4.92 
mmol) was added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(0.5290 grams, 1.24 mmol) dissolved in DMF (2 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (50 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x30 mL), saturated NaHCO3 solution (2x30 mL), and brine (2x30 mL).  The organic layer was 
dried over MgSO4 and concentrated to give 0.4718 grams of crude product mixture which was 
purified via flash chromatography (silica gel, 7:3 ethyl acetate:hexane) to give compound 3-6 
(0.3900 grams, 88% yield over 2 steps) as a clear oil.  Because this reaction pathway was 
deemed unsuitable for future use compound 3-6 was not fully characterized but the proton NMR 
spectrum obtained is located in Appendix A. 
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[Compound 3-7] EDCI (0.0645 grams, 0.34 mmol) and 4-dimethylaminopyridine (0.0678 
grams, 0.55 mmol) were dissolved in CH2Cl2 (1.5 mL).  The solution was then added to a 
mixture of compound 2-19 (0.1034 grams, 0.24 mmol) and compound 3-2 (0.0990 grams, 0.27 
mmol) in a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room 
temperature and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed 
with a saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back 
extracted with CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and 
concentrated to give 0.1918 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 1:1 hexane: ethyl acetate) to give compound 3-7 (0.0302 grams, 16% 
yield) as yellow oil.  Because this reaction pathway was deemed unsuitable for future use 
compound 3-7 was not fully characterized but the proton NMR spectrum obtained is located in 
Appendix A.  Other side products of interest were also obtained and proton NMR spectra of 
these compounds are located with the compound 3-7 spectrum. 
 
 85
 
[Compound 3-8] EDCI (0.0661 grams, 0.35 mmol) and 4-dimethylaminopyridine (0.0715 
grams, 0.59 mmol) were dissolved in CH2Cl2 (1.5 mL).  The solution was then added to a 
mixture of compound 2-19 (0.1076 grams, 0.25 mmol) and compound 3-6 (0.1026 grams, 0.29 
mmol) in a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room 
temperature and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed 
with a saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back 
extracted with CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and 
concentrated to give 0.2872 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 1:1 hexane: ethyl acetate) to give compound 3-8 (0.0713 grams, 37% 
yield) as yellow oil.  Because this reaction pathway was deemed unsuitable for future use 
compound 3-8 was not fully characterized but the proton NMR spectrum obtained is located in 
Appendix A.  Other side products of interest were also obtained and proton NMR spectra of 
these compounds are located with the compound 3-8 spectrum. 
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CHAPTER FOUR 
SYNTHESIS OF 2ND GENERATION SIMPLIFIED 
ANALOG  
4.1 Synthesis of New β-Hydroxyleucine Monomer 
 When I decided to pursue the simpler target molecule I wanted to keep as much of the 
WU-07047 synthesis in place as possible.  The only real change I envisioned in the procedure 
from the first analog was one extra peptide coupling step to add the extra amide bond in the top 
bridge.  I put the first of the two top bridge peptides in place by adding compound 2-9 to a 
solution of a mixed anhydride made from isobutyl chloroformate and Boc-5-aminovaleric acid 
(presented in Scheme 4.1A).  This reaction yielded compound 4-1 in an 83% crude yield after 
workup.  The crude reaction mixture was very clean with only very minor impurities present.  
This reaction was followed by the protection of the acid group with an allyl ester using chemistry 
previously discussed to form compound 4-2 in a 55% yield.  
I encountered problems during the subsequent bridge elongation reaction.  This reaction 
uses standard Boc deprotection/peptide coupling reaction conditions. In this case, not only did no 
reaction occur, but also no starting material was recovered.  When contemplating why this 
reaction failed, my hypothesis is that the coupling reaction is competing with an intramolecular 
cyclization reaction (Scheme 4.1B).  As soon as the Boc group is removed a protonated amine is 
formed, which is chemically inert.  When base is added in the next reaction, deprotonation leads 
to a free amine that can rapidly undergo a cyclization reaction to form a six membered ring 
intermediate.  This type of intramolecular ring formation is very fast and almost certainly 
outcompetes the intermolecular peptide coupling reaction.  I do not have definitive proof that the 
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cyclization occurred, but at the time I thought the best use of time was to completely avoid this 
possible problem.  
Scheme 4.1A: Top Bridge Construction 
 
Scheme 4.1B: Possible Reaction Failure Pathway 
 
 To do this, I made the dipeptide bridge before coupling it to the β-hydroxyleucine 
monomer.  The top bridge 4-3 was made in an 82% crude yield using a mixed anhydride 
coupling reaction between Boc-glycine and 5-aminovaleric acid (presented in Figure 4.2).  The 
crude product mixture was contaminated with a minor amount of the unreacted Boc-glycine and 
since the contaminant was so minor the mixture was carried on to the next reaction without 
further purification.  In order to form the completed β-hydroxyleucine monomer unit, compound 
2-15 was subjected to Boc-deprotection followed by peptide coupling with the newly formed top 
bridge 4-3.  This reaction afforded the finished monomer unit 4-4 in 40% yield.  The yield is low 
for this reaction, and there might be a chance that a similar type of short-lived intramolecular 
ring intermediate could be leading to the reduced yield.  Even with the low yield, we were still 
able to get enough of the monomer unit that we decided to move on with the synthesis.   
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At this point in the synthesis we were less interested in getting optimized yields for each 
reaction and more interested in getting the final molecule for biological testing.  If the final 
molecule has similar or only slightly improved biological activity in relation to the much easier 
to synthesize WU-07047 molecule, then we will use the more readily synthesized molecule in 
future biological studies. The synthetic optimization of the more complex molecule would be a 
waste.  If the more complex molecule was significantly more active, then we could improve 
reaction yields when that information became known.   
Scheme 4.2: β-hydroxyleucine Monomer Construction 
 
 With both complete β-hydroxyleucine monomer units in hand, we turned our attention to 
what proved to be a difficult esterification reaction.  We initially were met with very positive 
results with a 56% yield of the dimer 4-5 when the reaction was performed on a small scale.  
However, when we scaled the reaction up large portions of the unprotected acid form of the 
dimer were obtained.  This was discouraging because we thought based on what we had learned 
from section 3.3 Esterification Test Study that having the longer alkyl chain on the top bridge 
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would improve the reaction. However, it seemed that even having the one extra amide moiety in 
the top bridge complicated the reaction.  Perhaps there is an intramolecular hydrogen bond 
between the amide and the allyl ester carbonyl that is making it more susceptible to allyl 
deprotection.  Because of this we decided to go back to the beginning and replace the ally ester 
with the more robust allyl amide. This change would still introduce the double bond needed for 
the eventual ring closing olefin metathesis reaction at the end of the synthesis.  
Scheme 4.3: β-hydroxyleucine Dimer Construction 
 
 
4.2 Synthesis of WU-09060 
 The final synthesis of the WU-09060 molecule started with formation of the allyl 
substituted amide from acid 2-10 and allyl amine using standard EDCI coupling conditions 
(Scheme 4.4).  This reaction produced compound 4-6 in a 99% yield.  After removal of the Boc 
group, the top bridge was added to the molecule using another EDCI coupling reaction with 
compound 4-3 to produce the completed monomer unit 4-7 in a 47% yield.  Again this reaction 
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had lower yields than the reaction to put the simplified bridge in place, but it was good enough to 
carry on with the synthesis. 
Scheme 4.4: Starting Over With N-Allyl Protecting Group 
 
 We constructed the dimer molecule using a Steglich esterification between molecules 4-7 
and 2-19 to make compound 4-8 in a 53% yield (Scheme 4.5).  We were very pleased with the 
yield for this reaction. While it is not as good as the yield obtained for the WU-07047 molecule, 
it was still much better than the yields obtained when trying to do the same reaction with the 
tripeptide top bridge (Scheme 3.3).  After multiple test runs of this reaction, we noticed no loss 
of the allyl-moiety.  We can conclude that the allyl amide is a much more robust group.  
After the dimer was synthesized, I focused on removing and changing the protecting 
groups located on the molecule.  I started with the deprotection of Troc-carbamate group and the 
reprotection of the amine with the acetyl group needed in the final product. The sequence 
produced compound 4-9 in an 84% yield.  This was followed by the removal of the TBS group.  
This reaction was much more problematic than the Troc-deprotection reaction.  Under normal 
reaction conditions, I was able to obtain the desired product 4-10 in a 39% yield with 60% 
recovered starting material.  While the yield for this reaction is suboptimal, the mass balance for 
the reaction is exemplary.  When I tried altering the reaction conditions (lengthening the time of 
reaction, as well as adding additional equivalents of TBAF used) I still obtained roughly the 
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same amount (44%) of the desired product but did not obtain any unreacted starting material.  
Instead, I obtained a side product that was without the TBS group, but also missing the acetyl 
protecting group as well.  I am unsure if the acetyl group is being deprotected in this case or if 
the entire β-hydroxyleucine side chain is being eliminated because of the strong fluoride base in 
solution.  Either way, there is most likely a combination of time, reaction equivalents, and 
temperature that can be used to optimize the reaction. These changes can be explored if deemed 
necessary in the future.  It is also important to note that the purification and characterization of 
molecules 4-8 through 4-11 was very difficult (characterization) and not always possible 
(purification).  This subject is mentioned in detail in section 4.4 Experimental Procedures for 
Chapter Four Compounds. 
Scheme 4.5: N-Allyl Protected β-hydroxyleucine Dimer Construction 
 
 With the completed dimer in hand I was able to pursue the final target molecule.  The 
right side of the molecule, compound 2-8, was added to dimer molecule 4-10 using a COMU 
coupling (Scheme 4.6).  This reaction afforded compound 4-11 in a 47% yield.  The acyclic 
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molecule was then subjected to an olefin metathesis reaction to yield the final product WU-
09060 in 53-67% yield.  Polymer formation is the main factor affecting this reaction. This again 
is something that I believe can be fixed if deemed necessary with a more dilute solution of 
compound 4-11 while keeping the concentration of the Grubbs catalyst constant.  
 The synthesis led to WU-09060 in a 1.8% yield with a longest linear reaction sequence of 
10 steps.  While this reaction pathway was not as easy or high yielding as that of the WU-07047 
molecule, it did afford an analog with the extra hydrogen bond donating amide proton in the top 
bridge, and hence the opportunity to examine the biological impact of this bond.   
Scheme 4.6: Finishing the Molecule 
 
4.3 Biological Efficacy 
 After finishing the WU-09060 molecule, the molecule was tested for activity and 
compared to our original molecule WU-07047.  In order to do this, Ken Blumer and Michi Kanai 
OH
NHAc
O
O
HN
NHAllyl
O
O
NH
O
NHBoc
3
4-10
1. TFA/CH2Cl2
18 hours
2. COMU, TMP
DMF
24 hours NH
O
O
O
O
OH
NHAc
O
O
HN
NH
O
O
NH
O
H
N3
4-11
NH
O O
O
HO
O
2-8
47%
Grubbs Gen. 2
CH2Cl2
Reflux 18 hours
NH
O
O
O
O
OH
NHAc
O
O
HN
NH
O
O
NH
O
H
N3
WU-09060
53-67%
 94
used a new fluorescence resonance energy transfer (FRET) based study.1  This was done in order 
to move away from assays that used the expensive and hard to obtain isolated Gαq, receptor, and  
radio labeled GTP molecule, described in section 2.6: Biological Efficacy.  On a very basic level, 
FRET is a mechanism that measures the energy transfer between two chromophores in relation to 
the distance between the chromophores.2  This is performed by having an electronically excited 
donor chromophore transfer energy to an acceptor chromophore through a nonradiative dipole-
dipole coupling.2  How well this energy transfer occurs is inversely proportional to the distance 
between the donor and acceptor chromophores.2  In this way very small distance measurements 
can be made between molecules or proteins using ultraviolet-visible emission measurements.  
The assay we used in particular is a live cell assay that measures the change in secondary 
messenger calcium levels in the cell as a function of protein movement1,3,4 using FRET.  The 
more intricate details of the FRET technique (the proteins involved, UV absorbances, etc.) and 
the way in which we utilized it will not be discussed here as they are not the focus of this 
dissertation but the details can be found in the literature.1  A brief description of the core 
concepts behind this particular assay will be discussed. 
To start an agonist is added to the live cell to activate the Gq protein which increases the 
intracellular calcium concentration.  Then different concentrations of the different WU 
compounds are added and the change in the intracellular calcium concentration is measured.  If 
concentration of the calcium goes down it indicates the WU compound administered inhibits the 
G protein signaling pathway.  In our assay we tested concentrations (0, 10, 50, 100, and 200 µM) 
of both WU-09060 and WU-07047 in a buffer solution, and these were repeated in triplicate.  
This is presented in Figure 4.1.  The graph in Figure 4.1 plots ∆R/Ro (where ∆R/Ro is reporting 
changes in calcium concentrations as a function of FRET, where higher DR/Ro means higher 
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calcium concentrations) vs. the log of the concentrations of inhibitor studied.  As is shown in the 
graph as higher concentrations of the inhibitor are tested the ∆R/Ro unit decreases indicating less 
intracellular calcium.  Our WU-09060 molecule seems to work at a minimum concentration of 
50 µM. However, there appears to be no difference in potency between the WU-09060 and WU-
07047 molecules.  This leads us to believe that the extra intramolecular hydrogen bond that was 
added does not improve the activity of the compound. Hence, we can leave this more difficult to 
synthesize core structure behind and move on with the much easier WU-07047 core structure in 
the future. At the present, we are working with Greg Bowman’s computational group to better 
understand why this is the case. The current modeling effort suggests that both YM and WU-
07047 remain “floppy” when bound to Gαq. Hence, the rigidity of the structure would appear to 
have a minimal effect on binding, a suggestion that is consistent with the data obtained from 
WU-09060.  
Figure 4.1: FRET Study for WU-09060 and WU-07047 
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4.4 Experimental Procedures for Chapter Four Compounds 
 
[Compound 4-1] A stirred solution of Boc-5-aminovaleric acid (1.0381 grams, 4.78 mmol) and 
4-methylmorpholine (0.53 mL, 4.8 mmol) in 12mL of THF was cooled to -10°C.  Isobutyl 
chloroformate (0.62 mL, 4.7 mmol) was added and the reaction was allowed to stir for 30 
minutes.  The reaction was allowed to warm to 0 ° C at which time a solution of the 
hydrochloride salt of compound 2-9 (1.3178 grams, 7.18 mmol) in 7 mL of 1M NaOH was 
added.  The reaction was allowed to warm to room temperature and stir for 24 hours at which 
time it was diluted with H2O (50 mL).  The layers were separated and the aqueous layer was 
washed with ethyl acetate (2x50 mL).  The combined organic layers were then extracted with 
saturated NaHCO3 solution (3x50 mL).  All aqueous layers were combined and acidified to 
pH=2 with 1 M hydrochloric acid and extracted with ethyl acetate (3x100 mL).  The combined 
extractions were then dried over MgSO4, and concentrated to give compound 4-1 (1.1825 grams, 
71% yield) as a yellow foaming oil which was used without further purification.  Because this 
reaction pathway was deemed unsuitable for future use compound 4-1 was not fully 
characterized but the proton NMR spectrum obtained is located in Appendix A. 
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[Compound 4-2] Allyl bromide (2.20 mL, 25.4 mmol) was added to a stirred solution of 
compound 4-1 (1.1312 grams, 3.27 mmol) and NaHCO3 (1.1885 grams, 14.15 mmol) in 16 mL 
of DMF.  The reaction was stirred for 48 hours at which time it was diluted with H2O (50 mL).  
The aqueous layer was extracted with ethyl acetate (3x50 mL).  The combined organic layers 
were then washed with H2O (2x30 mL), dried over MgSO4, and concentrated to give 1.2564 
grams of crude product mixture which was purified via flash chromatography (silica gel, 1:1 
hexane: ethyl acetate) to give compound 4-2 (0.7005 grams, 55% yield) as a colorless oil.  
Because this reaction pathway was deemed unsuitable for future use compound 4-2 was not fully 
characterized but the proton NMR spectrum obtained is located in Appendix A.  
 
 
[Compound 4-3] A stirred solution of Boc-Glycine (2.1693 grams, 12.38 mmol) and 4-
methylmorpholine (1.40 mL, 12.7 mmol) in 30mL of THF was cooled to -10°C.  Isobutyl 
chloroformate (1.60 mL, 12.2 mmol) was added and the reaction was allowed to stir for 30 
minutes.  The reaction was allowed to warm to 0 ° C at which time a solution of 5-aminovaleric 
acid (2.2094 grams, 18.86 mmol) in 18 mL of 1M NaOH was added.  The reaction was allowed 
to warm to room temperature and stir for 24 hours at which time it was diluted with H2O (50 
mL).  The layers were separated and the aqueous layer was washed with ethyl acetate (2x50 mL).  
The combined organic layers were then extracted with saturated NaHCO3 solution (3x50 mL).  
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All aqueous layers were combined and acidified to pH=2 with 1 M hydrochloric acid and 
extracted with ethyl acetate (3x100 mL).  The combined extractions were then dried over 
MgSO4, and concentrated to give compound 4-3 (2.7833 grams, 82% yield) as a white waxy 
solid which was used without further purification.   
FTIR (neat) 3333, 2977, 2935, 1699, 1520, 1347, 1248, 1162 cm-1; 1H NMR (300 MHz,  CDCl3 
) δ 10.44 (br. s., 1 H), 6.74 (br. s., 1 H), 3.79 (d, J=5.9 Hz, 2 H), 3.29 (dt, J=6.4, 5.9 Hz, 2 H), 
2.36 (t, J=6.7 Hz, 2 H), 1.52 - 1.78 (m, 4 H), 1.45 (s, 9 H); 13C NMR (75 MHz,  CDCl3 ) δ 177.5, 
170.2, 156.5, 44.3, 39.0, 33.4, 28.6, 28.2, 21.8, 19.0;  HRMS m/z calculated for C12H22O5N2 
[M+Na]+ 297.1421, 297.1418 observed.    
 
 
[Compound 4-4] Trifluoroacetic acid (3 mL) was added to a stirred solution of compound 2-15 
(0.2497 grams, 0.87 mmol) in CH2Cl2 (4 mL).  Reaction was stirred at room temperature for 3 
hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane and concentrated three times.  The crude material was then 
dissolved in diethyl ether and concentrated once to ensure all the trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
The acid protected amine and compound 4-3 (0.2384 grams, 0.87 mmol) were dissolved 
in DMF (5 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (0.60 mL, 3.6 mmol) was 
OH
HN
OAllyl
O
O NH
O
NHBoc
3
 99
added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(0.3749 grams, 0.88 mmol) dissolved in DMF (4 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (50 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x30 mL), saturated NaHCO3 solution (2x30 mL), and brine (2x30 mL).  The organic layer was 
dried over MgSO4 and concentrated to give 0.2999 grams of crude product mixture which was 
purified via flash chromatography (silica gel, ethyl acetate) to give compound 4-4 (0.1548 grams, 
40% yield over 2 steps) as a clear oil.  Because this reaction pathway was deemed unsuitable for 
future use compound 4-4 was not fully characterized but the proton NMR spectrum obtained is 
located in Appendix A. 
 
 
[Compound 4-5] EDCI (0.0854 grams, 0.45 mmol) and 4-dimethylaminopyridine (0.0909 
grams, 0.74 mmol) were dissolved in CH2Cl2 (2 mL).  The solution was then added to a mixture 
of compound 2-19 (0.1304 grams, 0.30 mmol) and compound 4-4 (0.1548 grams, 0.35 mmol) in 
a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room temperature 
and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed with a 
saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back extracted with 
CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and concentrated to 
give 0.3288 grams of crude product mixture which was purified via flash chromatography (silica 
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gel, ethyl acetate) to give compound 4-5 (0.1452 grams, 56% yield) as yellow oil.  Because this 
reaction pathway was deemed unsuitable for future use compound 3-7 was not fully 
characterized but the proton NMR spectrum obtained is located in Appendix A.   
 
 
[Compound 4-6] To a stirred solution of compound 2-10 (1.2918 grams, 5.23 mmol) and 
hydroxybenzotriazole (1.1251 grams, 7.35 mmol) in CH2Cl2 (20 mL) was added allyl amine 
(0.43 mL, 5.72 mmol).  N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride or 
EDCl (1.4302 grams, 7.46 mmol) was dissolved in CH2Cl2 (20 mL) and added to the reaction 
flask followed by 4-methylmorpholine (0.57 mL, 5.2 mmol).  The reaction was stirred at room 
temperature for 18 hours at which time the organic mixture was washed with a saturated 
NaHCO3 solution (3x50 mL).  The aqueous layers were back extracted with CH2Cl2 (2x50 mL).  
All organic layers were combined and dried over MgSO4 and then concentrated to give 1.7495 
grams of crude product mixture which was purified via flash chromatography (silica gel, 7:3 
ethyl acetate:hexanes) to give compound 4-6 (1.4873 grams, 99% yield) as a clear oil.   
FTIR (neat) 3334, 2979, 2932, 2875, 1695, 1656, 1500, 1367, 1248, 1162, 1051, 907, 728, 646 
cm-1; 1H NMR (300 MHz,  CDCl3 ) δ 7.20 (br. s., 1 H), 5.81 (m, 2 H), 5.18 (dd, J=17.0, 1.2 Hz, 
1 H), 5.10 (dd, J=10.3, 1.5 Hz, 1 H), 4.32 (d, J=8.8 Hz, 1 H), 4.22 (d, J=2.9 Hz, 1 H), 3.85 (br. 
s., 2 H), 3.74 (d, J=2.33 Hz, 1 H), 1.59 - 1.88 (m, 1 H), 1.44 (s, 9 H), 1.02 (d, J=6.4 Hz, 3 H), 
0.90 (d, J=6.4 Hz, 3 H); 13C NMR (75 MHz,  CDCl3 ) δ 172.2, 156.1, 133.5, 115.8, 79.8, 76.0, 
55.6, 41.5, 30.3, 28.0, 18.9, 18.7;  HRMS m/z calculated for C14H26O4N2 [M+Na]
+ 309.1785, 
309.1786 observed.    
OH
NHBoc
NHAllyl
O
 101
 
[Compound 4-7] Trifluoroacetic acid (3 mL) was added to a stirred solution of compound 4-6 
(0.1130 grams, 0.39 mmol) in CH2Cl2 (4 mL).  Reaction was stirred at room temperature for 3 
hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane and concentrated three times.  The crude material was then 
dissolved in diethyl ether and concentrated once to ensure all the trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
To a solution of acid protected amine, compound 4-3 (0.0989 grams, 0.36 mmol), and 
hydroxybenzotriazole (0.0767 grams, 0.50 mmol) in CH2Cl2 (1.5 mL) was added a solution of   
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride or EDCl (0.0976 grams, 0.51 
mmol) dissolved in CH2Cl2 (1.5 mL) followed by 4-methylmorpholine (0.08 mL, 0.73 mmol).  
The reaction was stirred at room temperature for 18 hours at which time the organic mixture was 
washed with a saturated NaHCO3 solution (3x50 mL).  The aqueous layers were back extracted 
with CH2Cl2 (2x50 mL).  All organic layers were combined and dried over MgSO4 and then 
concentrated to give 0.1408 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 9:1 ethyl acetate:methanol) to give compound 4-7 (0.0749 grams, 
47% yield) as a clear oil.   
FTIR (neat) 3307, 2965, 2933, 2874, 1650, 1512, 1368, 1249, 1167, 905, 725, 647 cm-1; 1H 
NMR (300 MHz, CDCl3 ) δ 7.26 (br. s., 1 H), 7.14 (br. s., 1 H), 6.97 (br. s., 1 H), 5.64 - 5.91 (m, 
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2 H), 5.16 (d, J=17.8 Hz, 1 H), 5.10 (d, J=10.5 Hz, 1 H), 4.61 (dd, J=8.2, 1.8 Hz, 1 H), 3.63 - 
3.91 (m, 5 H), 3.27 (dt, J=6.4, 6.4 Hz, 2 H), 2.32 (t, J=7.0 Hz, 2 H), 1.59 - 1.78 (m, 3 H), 1.52 
(m, 2 H), 1.44 (s, 9 H), 1.02 (d, J=6.4 Hz, 3 H), 0.86 (d, J=6.4 Hz, 3 H); 13C NMR (75 MHz,  
CDCl3 ) δ 173.9, 172.0, 169.9, 156.3, 133.6, 116.1, 80.0, 77.2, 76.2, 54.1, 44.1, 41.7, 38.6, 35.2, 
30.4, 28.6, 28.2, 22.6, 19.0, 18.8;  HRMS m/z calculated for C21H38O6N4 [M+Na]
+ 465.2684, 
465.2707 observed.    
 
 
[Compound 4-8] EDCI (0.0423 grams, 0.22 mmol) and 4-dimethylaminopyridine (0.0438 
grams, 0.36 mmol) were dissolved in CH2Cl2 (1 mL).  The solution was then added to a mixture 
of compound 2-19 (0.0675 grams, 0.15 mmol) and compound 4-7 (0.0749 grams, 0.17 mmol) in 
a reaction flask cooled to 0 ° C.  This reaction mixture was allowed to warm to room temperature 
and stir for 24 hours at which time it was diluted with CH2Cl2 (50 mL) and washed with a 
saturated NaHCO3 solution (3x30 mL).  The combined aqueous layers were back extracted with 
CH2Cl2 (2x30 mL).  All organic layers were combined, dried over MgSO4, and concentrated to 
give 0.1418 grams of crude product mixture which was purified via flash chromatography (silica 
gel, 9:1 ethyl acetate:methanol) to give compound 4-8 (0.0697 grams, 53% yield) as yellow oil.   
Compound 4-8 was not able to be completely purified.  There are some very notable peaks in the 
proton and carbon NMR spectra that can be attributed to some sort of aromatic protons (~7.5ppm 
in proton, and ~130ppm in carbon).  This impurity could not be separated from the product and 
was carried through to the next step.  There also seems to be possible rotamers present (strange 
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splitting patterns in proton NMR as well as peaks split in carbon NMR) which I attribute to the 
fact that the new intramolecular hydrogen bond placed in the new top bridge is not allowing for 
free rotation of all bonds and therefore favoring certain conformations.  This is not a fact but 
merely a suggestion as to the identity of some of the extra peaks present.     
FTIR (neat) 3296, 2959, 2931, 2859, 1740, 1651, 1505, 1367, 1252, 1169, 1094, 909, 835, 777, 
729, 541 cm-1; 1H NMR (300 MHz, CDCl3 ) δ 6.62 (d, J=8.2 Hz, 1 H), 5.79 (m, 2 H), 5.28 - 5.54 
(m, 1 H), 5.16 (d, J=17.0 Hz, 1 H), 5.10 (d, J=11.1 Hz, 1 H), 4.49 - 4.92 (m, 4 H), 4.23 (dd, 
J=7.6, 2.3 Hz, 1 H), 3.90 (dd, J=4.1, 2.3 Hz, 1 H), 3.83 (d, J=4.1 Hz, 2 H), 3.79 (d, J=5.9 Hz, 2 
H), 3.00 - 3.49 (m, 2 H), 2.28 (m, 2 H), 1.74 - 2.11 (m, 2 H), 1.49 - 1.73 (m, 4 H), 1.44 (s, 9 H), 
0.76 - 1.13 (m, 21 H), 0.09 (s, 3 H), 0.06 (s, 3 H); 13C NMR (75 MHz,  CDCl3 ) δ 173.4, 171.3, 
170.0, 169.6, 169.1, 154.4, 133.8, 132.1, 132.0, 131.9, 128.5, 128.4, 116.3, 95.3, 94.2, 82.7, 77.9, 
76.4, 75.6, 75.0, 74.7, 74.6, 59.7, 55.5, 55.2, 41.9, 38.7, 35.2, 33.8, 33.3, 29.2, 28.7, 28.3, 25.8, 
22.2, 20.0, 18.9, 18.5, 18.2, 18.0, 17.7, 17.6, 16.9, -4.29, -4.33, -4.5, -4.6;  HRMS m/z calculated 
for C36H64O10N5Si1Cl3 [M+Na]
+ 884.3360, 884.3373 observed.    
 
 
[Compound 4-9] Compound 4-8 (0.0697 grams, 0.08 mmol) was dissolved in acetic anhydride 
(1.2 mL, 12.72 mmol) and added via syringe to a flask charged with freshly activated Zinc 
(0.2132 grams, 3.26 mmol).  To this was added triethylamine (0.03 mL, 0.21 mmol).  This 
reaction mixture was sonnicated at 0 C for four hours after which the reaction contents were 
diluted with methanol (50 mL) and filtered to remove solid.  The filtrate was then concentrated 
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(temperature should not exceed 40 C to help prevent racemization), dissolved in methanol (50 
mL) then concentrated again.  This process was repeated three times to help remove excess 
acetic anhydride.  The final concentration yielded 0.1707 grams of crude product mixture which 
was purified via flash chromatography (silica gel, 9:1 ethyl acetate:methanol) to give compound 
4-9 (0.0493 grams, 84% yield) as a yellow oil.   
Compound 4-9 could not be completely purified.  There are some very notable peaks in 
the proton and carbon NMR spectra that can be attributed to some sort of aromatic protons 
(~7.5ppm in proton, and ~130ppm in carbon).  This impurity could not be separated from the 
product and was carried through to the next step.  There also seems to be possible rotamers 
present (strange splitting patterns in proton NMR as well as peaks split in carbon NMR) which I 
attribute to the fact that the new intramolecular hydrogen bond placed in the new top bridge is 
not allowing for free rotation of all bonds and therefore favoring certain conformations.  This is 
not a fact but merely a suggestion as to the identity of some of the extra peaks present.     
FTIR (neat) 3306, 2961, 2931, 2858, 1720, 1655, 1530, 1367, 1252, 1171, 1058, 838, 777cm-1; 
1H NMR (300 MHz, CDCl3) δ 6.54 - 7.08 (m, 3 H), 5.67 - 6.02 (m, 1 H), 5.36 - 5.55 (m, 1 H), 
5.00 - 5.26 (m, 3 H), 4.71 (d, J=8.2 Hz, 1 H), 4.66 (m, 1 H), 4.36 (dd, J=7.3, 2.1 Hz, 1 H), 3.58 - 
3.97 (m, 5 H), 3.06 - 3.43 (m, 2 H), 2.30 (t, J=7.3 Hz, 2 H), 2.02 (s, 3 H), 1.92 - 2.11 (m, 1 H), 
1.74 - 1.89 (m, 1 H), 1.66 (m, 2 H), 1.54 (m, 2 H), 1.44 (s, 9 H), 0.79 - 1.07 (m, 21 H), 0.09 (s, 3 
H), 0.06 (s, 3 H); 13C NMR (75 MHz,  CDCl3 ) δ 173.4, 171.3, 170.6, 169.5, 169.4, 156.0, 133.9, 
132.1, 131.9, 128.5, 128.4, 118.4, 116.1, 79.9, 77.7, 77.2, 76.9, 75.4, 55.1, 54.0, 53.7, 44.2, 41.9, 
38.7, 35.3, 33.9, 33.0, 29.6, 29.5, 29.3, 28.5, 28.3, 25.8, 23.1, 22.2, 19.9, 18.9, 18.1, 18.0, 17.7, 
17.5, 17.0, -4.3, -4.4, -4.5, -4.9;  HRMS m/z calculated for C35H65O9N5Si1 [M+Na]
+ 750.4444, 
750.4448 observed.    
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[Compound 4-10] A solution of compound 4-9 (0.0717 grams, 0.098 mmol) dissolved in THF 
(2 mL) was cooled to 0 C.  To this solution was added a 1 M solution of tetra-n-
butylammonium fluoride (0.30 mL, 0.30 mmol).  The reaction mixture was stirred at 0 C for 3 
hours after which the contents were poured into a saturated solution of ammonium chloride (25 
mL).  The aqueous layer was extracted with ethyl acetate (3x 30 mL).  The combined organic 
layers were washed with water (2x 20 mL), a brine solution (20 mL), dried over MgSO4, and 
concentrated to give 0.0638 grams of crude product mixture which was purified via flash 
chromatography (silica gel, 9:1 ethyl acetate:methanol) to give compound 4-10 (0.0233 grams, 
39% yield) as a clear oil.  Unreacted starting material was also obtained (0.0369 grams or 60% 
recovered starting material).  
Compound 4-10 could not be completely purified.  This is evident by the number of 
peaks in the carbon NMR spectrum.  There also seems to be possible rotamers present (strange 
splitting patterns in proton NMR as well as peaks split in carbon NMR) which I attribute to the 
fact that the new intramolecular hydrogen bond placed in the new top bridge is not allowing for 
free rotation of all bonds and therefore favoring certain conformations.  This is not a fact but 
merely a suggestion as to the identity of some of the extra peaks present.      
FTIR (neat) 3294, 2965, 2932, 2875, 1644, 1525, 1367, 1245, 1168, 920, 731 cm-1; 1H NMR 
(300 MHz,  CDCl3 ) δ 7.32 (d, J=10.0 Hz, 1 H), 6.91 (m, 3 H), 5.88 (t, J=5.9 Hz, 1 H), 5.77 (m, 
1 H), 5.18 (dd, J=17.6, 1.2 Hz, 1 H), 5.13 (dd, J=10.6, 1.2 Hz, 1 H), 5.04 (dd, J=8.5, 2.1 Hz, 1 
H), 4.83 (m, 1 H), 4.81 (dd, J=9.1, 2.1 Hz, 1 H), 3.64 - 3.97 (m, 5 H), 2.72 - 3.63 (m, 2 H), 2.28 
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(m, 2 H), 2.04 (s, 3 H), 1.84 - 2.02 (m, 1 H), 1.47 - 1.82 (m, 5 H), 1.44 (s, 9 H), 0.80 - 1.12 (m, 
12 H); 13C NMR (75 MHz,  CDCl3 ) δ 173.9, 173.4, 171.2, 170.8, 170.74, 170.70, 169.8, 156.7, 
133.6, 133.3, 116.9, 116.6, 80.1, 78.8, 77.8, 77.7, 55.3, 52.9, 52.2, 44.5, 42.2, 42.0, 41.7, 38.7, 
38.1, 35.30, 35.25, 30.5, 29.6, 29.4, 29.2, 28.6, 28.33, 28.27, 25.8, 22.9, 22.8, 20.7, 20.2, 19.5, 
19.2, 19.0, 18.9, 18.2, 13.6;  HRMS m/z calculated for C29H51O9N5 [M+Na]
+ 636.3579, 
636.3571 observed.    
 
 
[Compound 4-11] Trifluoroacetic acid (1.5 mL) was added to a stirred solution of compound 4-
10 (0.0342 grams, 0.056 mmol) in CH2Cl2 (3 mL).  Reaction was stirred at room temperature for 
3 hours after which the solvent was removed under reduced pressure.  The crude material was 
dissolved in dichloromethane and concentrated three times.  The crude material was then 
dissolved in diethyl ether and concentrated once to ensure all the trifluoracetic acid was 
removed.  The crude acid protected amine product was used in the next reaction without further 
purification.   
The acid protected amine and compound 2-8 (0.0180 grams, 0.058 mmol) were dissolved 
in DMF (0.5 mL) and cooled to 0 oC.  2,2,6,6-Tetramethylpiperidine (0.03 mL, 0.18 mmol) was 
added to the reaction mixture followed by 1-Cyano-2-ethoxy-2-
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oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate or COMU 
(0.0250 grams, 0.058 mmol) dissolved in DMF (1 mL).  The reaction was stirred at 0 oC and 
allowed to warm to room temperature overnight.  After 24 hours the reaction mixture was diluted 
with ethyl acetate (40 mL).  The organic layer was then washed with 1 M hydrochloric acid 
(2x20 mL), saturated NaHCO3 solution (2x20 mL), and brine (2x20 mL).  The organic layer was 
dried over MgSO4 and concentrated to give 0.0276 grams of crude product mixture which was 
purified via flash chromatography (silica gel, 9:1 ethyl acetate:methanol) to give compound 4-11 
(0.0208 grams, 47% yield over 2 steps) as a clear oil.   
While Compound 4-11 could be completely purified there are some strange peaks and 
splittings in the carbon and proton NMR spectra. This can possibly be attributed to rotamers 
which I attribute to the fact that the new intramolecular hydrogen bond placed in the new top 
bridge is not allowing for free rotation of all bonds and therefore favoring certain conformations.  
This may explain some of the strange splitting and peaks present in both spectra.  This is not a 
fact but merely a suggestion as to the identity of some of the extra peaks present.     
FTIR (neat) 3292, 3070, 2961, 2927, 2874, 2856, 1741, 1645, 1532, 1373, 1239, 920, 731 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.59 - 7.75 (m, 1 H), 7.16 - 7.34 (m, 5 H), 7.03 (d, J=8.6 Hz, 1 
H), 6.92 (d, J=8.9 Hz, 1 H), 6.62 (t, J=5.4 Hz, 1 H), 6.56 (d, J=5.1 Hz, 1 H), 6.47 (t, J=5.9 Hz, 1 
H), 5.66 - 5.91 (m, 1 H), 5.33 - 5.50 (m, 1 H), 5.27 (dd, J=9.4, 3.3 Hz, 1 H), 5.18 (dd, J=17.0, 1.4 
Hz, 1 H), 5.13 (dd, J=10.2, 1.0 Hz, 1 H), 5.08 (dd, J=7.6, 3.2 Hz, 1 H), 5.02 (d, J=16.8 Hz, 1 H), 
4.98 (d, J=10.2 Hz, 1 H), 4.74 (dd, J=8.7, 1.8 Hz, 1 H), 4.16 - 4.32 (m, 2 H), 4.02 - 4.15 (m, 1 
H), 3.60 - 3.90 (m, 4 H), 3.16 - 3.45 (m, 2 H), 3.01 - 3.16 (m, 2 H), 2.18 - 2.40 (m, 4 H), 2.04 (s, 
3 H), 1.94 (s, 3 H), 1.56 - 1.81 (m, 4 H), 1.42 - 1.55 (m, 2 H), 0.78 - 1.12 (m, 12 H); 13C NMR 
(126 MHz,  CDCl3 ) δ 173.8, 172.7, 171.5, 171.2, 170.8, 170.4, 169.9, 169.7, 169.6, 136.0, 
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133.52, 133.49, 131.3, 129.4, 128.48, 128.45, 127.08, 127.02, 119.8, 119.7, 116.9, 78.3, 77.4, 
76.03, 76.00, 75.9, 55.4, 53.3, 53.20, 53.15, 43.3, 42.2, 41.7, 38.8, 38.3, 37.5, 35.9, 35.5, 34.7, 
34.6, 30.8, 29.7, 28.5, 28.4, 23.1, 22.9, 22.7, 22.6, 22.5, 22.4, 19.3, 19.1, 19.0, 18.8, 17.9; HRMS 
m/z calculated for C40H60O11N6 [M+Na]
+ 823.4212, 823.4209 observed.    
 
 
[WU-09060] A solution of Grubbs 2nd generation catalyst (0.0011 grams, 0.0013 mmol) 
dissolved in CH2Cl2 (1 mL) was added to a stirred and refluxing solution of compound 4-11 
(0.0053 grams, 0.0066 mmol) in CH2Cl2 (4 mL, 0.0013M solution of substrate total).  The 
reaction was refluxed for 24 hours at which time the reaction contents were concentrated.  The 
crude product mixture was purified via flash chromatography (silica gel, 85:15 ethyl 
acetate:methanol) to give compound WU-09060 (0.0034 grams, 67% yield; the reaction was run 
a second time with 0.0208 grams of starting material and ended with 0.0106 grams of product 
and a yield of 53%) as a brown oily solid.   
Do notice that now that the ring is tied together the splitting patterns in the proton NMR 
spectrum and the amount of peaks in the carbon spectrum are very clean and match up perfectly 
with what is expected.  Since the molecule is tied together in one conformation it might explain 
why the spectra for WU-09060 is so “clean” as compared to compounds 4-8, 4-9, 4-10, and 4-11 
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where there could be multiple peaks due to a balance between a molecule who’s bonds are free 
to rotate and favored conformations (possibly due to the intramolecular hydrogen bond present). 
FTIR (neat) 3293, 3079, 3067, 2961, 2927, 2874, 2856, 1743, 1651, 1533, 1374, 1261, 1234, 
1193, 731 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.86 (d, J=8.3 Hz, 1 H), 7.82 (d, J=5.9 Hz, 1 H), 
7.15 - 7.40 (m, 5 H), 6.54 (d, J=6.9 Hz, 1 H), 6.46 (br. s., 1 H), 6.38 (d, J=8.3 Hz, 1 H), 6.31 (br. 
s., 1 H), 5.07 (m, 1 H), 5.01 (d, J=8.8 Hz, 1 H), 4.91 (m, 1 H), 4.67 (d, J=6.9 Hz, 1 H), 4.59 (d, 
J=11.3 Hz, 1 H), 4.37 - 4.47 (m, 1 H), 4.33 (d, J=8.3 Hz, 1 H), 3.93 (d, J=9.8 Hz, 2 H), 3.47 - 
3.87 (m, 3 H), 3.32 (d, J=13.2 Hz, 1 H), 2.85 - 3.12 (m, 3 H), 2.27 - 2.52 (m, 3 H), 2.24 (s, 3 H), 
2.12 - 2.21 (m, 1 H), 2.04 (s, 3 H), 1.96 - 2.11 (m, 1 H), 1.87 (m, 1 H), 1.43-1.78 (m, 4 H), 0.75 - 
1.22 (m, 12 H); 13C NMR (126 MHz,  CDCl3 ) δ 175.2, 171.5, 171.2, 170.8, 170.6, 170.2, 170.0, 
169.6, 137.1, 129.7, 128.5, 128.3, 127.0, 122.7, 78.2, 76.8, 76.6, 56.5, 52.2, 51.8, 44.0, 39.8, 
38.5, 38.0, 37.1, 35.2, 30.8, 30.4, 29.7, 22.8, 22.4, 21.5, 20.0, 19.0, 18.9, 18.4;  HRMS m/z 
calculated for C38H56O11N6 [M+H]
+ 773.4080, 773.4082 observed.    
 
 
 
 
 
 
 
 
 
 
 110
4.5 Chapter Four References 
                                                        
1. Thestrup, T.; Litzlbauer, J.; Bartholomaus, I.; Mues, M.; Russo, L.; Dana, H.; Kovalchuk, Y.; 
Liang, Y.; Kalamakis, G.; Laukat, Y.; Becker, S.; Witte, G.; Geiger, A.; Allen, T.; Rome, L. 
C.; Chen, T. W.; Kim, D. S.; Garaschuk, O.; Griesinger, C.; Griesbeck, O.  Nature Methods, 
2014, 11, 175-182. 
2. Förster, T.  Ann. Phys. 1948, 2, 55-75. 
3. Tsien, R. Y.  Ann. Review Biochem. 1998, 67, 509-544. 
4. Johnsson, T.; Waldburger, C. D.; Sauer, R. T.  Biochemistry 1996, 35, 4795-4802. 
 111
CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Conclusions 
 In conclusion, we have developed a convergent synthetic approach to a class of 
simplified analogs of the selective Gq inhibitor YM (Figure 5.1).  The first of these analogs, WU-
07047, was not as potent as YM, but it did inhibit Gq and after some initial studies it appears to 
retain G protein selectivity characteristics like the natural product.  We were able to synthesize 
the WU-07047 compound in a 6.4% overall yield with a longest linear reaction sequence of 10 
steps.  More importantly, the synthetic approach that has been developed allows complete 
control over all the stereocenters in the molecule which will be paramount in the future of the 
project.  Even though we were able to make the WU-07047 molecule and it was active towards 
the target protein, we wanted to see if we could change the core structure of the simplified analog 
to increase the potency. 
Figure 5.1: The Synthesis As I Leave It 
 
In order to increase the potency we hypothesized that adding an amide bond into the top 
bridge of the molecule, and thereby reintroducing an intramolecular hydrogen bond (labeled as 1 
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in Figure 5.1), might position the β-hydroxyleucine side chain of the molecule in a favorable 
orientation.  This molecule turned out to be much more difficult to synthesize than WU-07047, 
but after much trial and error we were able to synthesize our second more complex WU-09060 
molecule.  This molecule was completed in a 1.8% overall yield with a longest linear reaction 
sequence of 10 steps.  During the synthesis of the WU-09060 molecule we were also able to 
probe the effects of the top bridging structure of the molecule on ease of overall molecule 
synthesis.  This seems to have larger implications on the synthesis of this class of molecules.  As 
stated in chapter 3, people have been able to get close to making YM but adding the extra β-
hydroxyleucine side chain on the molecule is not attainable.  We think that we have shown why 
this is the case.   
Initial biological testing has shown that the reintroduction of the intramolecular hydrogen 
bond has no effect on the potency of the molecule.  With this in mind, it does not appear that 
including the extra intramolecular hydrogen bond in place will be done in the future.  The fact 
that there is no increase in potency does not justify the increase in synthetic (being synthesis, 
purification, and characterization) complexity needed for such analogs.  This fact will help shape 
the direction the Moeller group takes in future efforts on this project. 
 
5.2 Future Directions 
Now that a basic core structure and analog has been established for this project, we can 
start planning for the future.  To this end, we have started some initial collaborations to study the 
impact of the WU-07047 molecule in G protein biological assays.  As of now, we have sent 
seven different groups around the world the WU-07047 molecule for initial testing.  One of these 
collaborations has already yielded promising initial results.1 One of those groups, the Osei-
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Owusu group, is studying the mechanisms that regulate uterine vascular tone and myogenic 
response wanted to test if augmented signaling of G protein Gq increased uterine artery myogenic 
tone in RGS2 deficiency.1  It was discovered that after treating uterine arteries with the WU-
07047 molecule that it reduced myogenic tone in all genotypes studied.1  Because of this, we 
were able to confirm that G protein signaling regulation by RGS2 plays a central role in 
modulating myogenic tone development in uterine arteries.1  Being able to provide the molecule 
to be used to help study these biological systems is very rewarding. 
Along with the biological collaborations, we want to start making multiple analogs to 
start probing the structural activity relationship of this class of molecule with Gq and eventually 
other G proteins.  To do this we need to pick what to change about our original molecule.  While 
the same core structure will be used, there are many ways in which we can modify the right and 
left hand sides of the molecule.  As discussed before, we have the ability to change any of the 
stereocenters in the molecule and are currently in the process of synthesizing a molecule to this 
end, presented in Figure 5.2A.   
Figure 5.2: Two New Analogs in Progress 
 
Along with changing the stereocenters in the molecule, we can also change the groups 
around the outside of the molecule.  As presented in Figure 5.3 there are many different spots, 
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replacing some of the amino acids utilized.  There is one target that we are pursuing at this time 
which puts an aryl bromide on the R12 position, as presented in Figure 5.2B.  We plan on using 
this type of aryl bromide group as the basis of a linker strategy to put these molecules down on a 
microelectrode array for a binding assay developed previously.2  This chemistry, putting 
molecules down on a microelectrode array, has been researched extensively in the Moeller group 
and we hope to use our binding assay as a way to rapidly screen molecules before testing them in 
more sophisticated biological assays.2  This approach will become especially important in the 
future when one builds libraries of the molecules in order to optimize the binding and efficacy of 
a selected core scaffold. While the first attempt at this approach does use the more difficult to 
synthesize core molecule, containing the extra amide bond, the R12 position is the most optimal 
place to put this linker group at this time. Strategies without the amide can be undertaken, if the 
location of the linker is in an appropriate place.    
Figure 5.3: Possible Synthetic Targets 
 
 
I would also suggest either changing the R9-R11 positions of the phenyl ring or perhaps 
replace the phenyl group with something larger or smaller.  It was originally shown that the 
phenyl ring is located in a large hydrophobic binding pocket in the X-ray crystal structure,3 
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dynamic structure. There are also suggestions that the binding pocket in other G proteins might 
contain a histidine group, a situation that would suggest a potential tyrosine replacement for the 
phenyl alanine in the YM analogs. Either way, it appears that the group may play a role in the 
binding and selectivity of the molecule suggesting that this might be a good location to begin 
efforts to increase potency of the molecule or perhaps in the future change the selectivity of the 
molecule. Efforts along those lines are underway.   
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APPENDIX A 
SPECTRAL DATA 
 
1H Spectrum for Compound 2-1 
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13C Spectrum for Compound 2-1 
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1H Spectrum for Compound 2-2 
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13C Spectrum for Compound 2-2 
 
DTR_03_100_carbongood
220 200 180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
3
6
.
3
0
3
6
.
4
1
4
8
.
3
0
4
8
.
5
9
4
8
.
8
6
4
9
.
1
5
4
9
.
4
4
4
9
.
7
1
5
0
.
0
0
5
3
.
9
1
5
4
.
3
7
1
1
8
.
9
6
1
2
1
.
0
8
1
3
2
.
6
8
1
3
4
.
5
1
1
7
3
.
4
4
CH2 NH
OHO
O
F
F
F
 121
 
1H Spectrum for Compound 2-3 
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13C Spectrum for Compound 2-3 
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1H Spectrum for Compound 2-4 
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13C Spectrum for Compound 2-4 
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1H Spectrum for Compound 2-5 
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1H Spectrum for Compound 2-6 
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1H Spectrum for Compound 2-7 
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1H Spectrum for Compound 2-8 
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13C Spectrum for Compound 2-8 
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1H Spectrum for Compound 2-10 
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13C Spectrum for Compound 2-10 
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1H Spectrum for Compound 2-11 
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1H Spectrum for Compound 2-12 
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1H Spectrum for Compound mixture 2-13 & 2-14 
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1H Spectrum for Compound 2-14 
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1H Spectrum for Compound 2-15 
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1H Spectrum for Compound 2-16 
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13C Spectrum for Compound 2-16 
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1H Spectrum for Compound 2-17 
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13C Spectrum for Compound 2-17 
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1H Spectrum for Compound 2-18 
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13C Spectrum for Compound 2-18 
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1H Spectrum for Compound 2-19 
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13C Spectrum for Compound 2-19 
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1H Spectrum for Compound 2-20 
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1H Spectrum for Compound 2-21 
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13C Spectrum for Compound 2-21 
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1H Spectrum for Compound 2-22 
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13C Spectrum for Compound 2-22 
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1H Spectrum for Compound 2-23 
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13C Spectrum for Compound 2-23 
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1H Spectrum for Compound 2-23a 
 
DTR_07_029_protongood.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
2.882.7222.589.0512.342.240.911.732.882.001.970.800.912.770.880.840.830.820.840.840.80
CH3
CH3
OTBS
NHAc
O
O
CH3CH3
NH
O OAllyl
O
NHBoc
DTR_07_029_protongood.esp
6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)
0.01
0.02
0.03
0.04
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 153
    
13C Spectrum for Compound 2-23a 
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1H Spectrum for Compound 2-24 
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13C Spectrum for Compound 2-24 
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1H Spectrum for Compound 2-25 
 
DTR_07_040_proton.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
14.0512.7215.064.126.562.766.126.298.851.904.092.064.131.853.682.178.262.005.831.491.761.922.021.7911.18
CH3
CH3
NH
O
OAllyl
OH
AcHN
O
O
CH3
CH3
O
NH
O
O
O
NHAc
CH2
DTR_07_040_proton.esp
6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)
0.05
0.10
0.15
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 157
 
13C Spectrum for Compound 2-25 
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1H Spectrum for Compound WU-07047 
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13C Spectrum for Compound WU-07047 
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1H Spectrum for Compound 3-1 
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1H Spectrum for Compound 3-2 
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1H Spectrum for Compound 3-3 
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1H Spectrum for Compound 3-4 
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1H Spectrum for Compound 3-5 
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1H Spectrum for Compound 3-6 
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1H Spectrum for Compound 3-7 
DTR_09_023_column_X
6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
7.9540.816.2413.663.073.170.890.843.005.441.000.851.870.970.52
OTBS
NHTroc
O
O
NH
O
O
O
NMeBoc
DTR_09_023_column_X
6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)
0
0.025
0.050
0.075
N
o
r
m
a
l
i
z
e
d
 
I
n
t
e
n
s
i
t
y
 167
 
1H Spectrum for Compound 3-7 Side Product  
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1H Spectrum for Compound 3-7 Side Product 2 
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1H Spectrum for Compound 3-7 Side Product 3 
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1H Spectrum for Compound 3-8 
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1H Spectrum for Compound 3-8 Side Product 
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1H Spectrum for Compound 4-1 
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1H Spectrum for Compound 4-2 
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13C Spectrum for Compound 4-11 
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13C Spectrum for Compound WU-09060 
 
